<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0007.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0009.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h39" class="calibre7"></a><a id="page_3-1" class="calibre7"></a><a href="part0002.html#rh45" class="calibre7">ESOPHAGEAL AND GASTRIC DISORDERS</a></h2>
<p class="h">D<small class="calibre30">YSPHAGIA</small></p>
<p class="bl"><span class="sbl">•</span> Oropharyngeal: inability to propel food from mouth through UES into esophagus</p>
<p class="bl"><span class="sbl">•</span> Esophageal: difficulty swallowing &amp; passing food from esophagus into stomach</p>
<p class="capf"><b class="calibre4">Figure 3-1 Etiologies of and approach to dysphagia</b> <span class="s2">(<i class="calibre3">NCP Gastrohep</i> 2008;5:393; <i class="calibre3">Neurogastro</i> 2012;24:57)</span></p>
<p class="image"><img src="../images/00051.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Structural dysphagia <span class="s">(solids &gt; liquids; <i class="calibre3">JAMA</i> 2015;313:18; <i class="calibre3">Gastro</i> 2018;155:1022)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Oropharyngeal</b></p>
<p class="bl1">Zenker’s divertic. (pharyngeal pouch): in elderly, a/w aspir., dx w/ video fluoro, Rx endo/surg</p>
<p class="bl1">Malignancy; proximal strictures/rings/webs; infection; radiation injury; goiter; osteophytes</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Esophageal</b></p>
<p class="bl1">Rings (intermittent dysphagia, concentric obstructing tissue, eg, Schatzki ring): near GE jxn, a/w food impaction, linked to GERD; Rx w/ PPI, dilation</p>
<p class="bl1">Webs (nonconcentric): usually prox, can be a/w Fe defic. (Plummer-Vinson synd.)</p>
<p class="bl1">Peptic or XRT strictures, foreign body, tumor, vascular compression (dysphagia lusoria)</p>
<p class="bl1">Infxn esophagitis: odynophagia &gt; dysphagia; often immunosupp w/ <i class="calibre3">Candida</i>, HSV, CMV</p>
<p class="bl1">Pill esophagitis: odynophagia &gt; dysphagia; NSAID, KCl, bisphosp., doxy &amp; tetracycline</p>
<p class="bl1">Eosinophilic esophagitis: often young/middle-aged ♂. Dx: &gt;15 eos/hpf on bx, esoph dysfxn (ie, dysphagia, food impaction). Rx: 1<sup class="calibre15">st</sup> line is PPI (½ respond); alternative (or if fail PPI) is <b class="calibre4">3Ds</b>: 1<sup class="calibre15">st</sup> try elimination <b class="calibre4">D</b>iet (∅ milk, soy, eggs, wheat, nuts, fish); if no Δ, <b class="calibre4">D</b>rugs (swallow inh steroids); if ongoing sx &amp; stricturing, <b class="calibre4">D</b>ilation.</p>
<p class="h2a">Neuromuscular dysphagia <span class="s">(solids &amp; liquids; <i class="calibre3">Neurogastero Motil</i> 2015;27:160 &amp; 2016;22:6)</span></p>
<p class="bl"><span class="sbl">•</span> Caused by aberrant motility or innervation of oropharynx/esophagus</p>
<p class="bl"><span class="sbl">•</span> Oropharyngeal: consider CNS disorders (eg, stroke, ALS, myopathies, CNS tumors)</p>
<p class="bl"><span class="sbl">•</span> Esophageal: motility disorder w/ dysphagia, chest pain, GERD; dx: conventional or high-res manometry w/ esophageal pressure topography. Chicago classification v3.0:</p>
<p class="ol"><span class="sol">1.</span> <span class="underline">Incomplete LES relaxation</span>: <i class="calibre3">Isolated EGJ outflow obstruction or achalasia. Achalasia:</i> simult. ↓ amp contractions &amp; ↓ LES relaxation; barium swallow w/ dilated esophagus &amp; distal “bird’s beak” narrowing; mostly idiopathic, although can be a/w Chagas; Rx: pneumatic dilation as effective as Heller myotomy (local expertise dependent) <span class="s1r">(<i class="calibre3">Gut</i> 2016;65:732)</span>; peroral endoscopic myotomy; CCB/nitrates/PDEi; Botox if ∅ surg cand.</p>
<p class="ol"><span class="sol">2.</span> <span class="underline">Major motility disorders</span>: <i class="calibre3">Absent contractility; Distal spasm</i> (uncord. peristalsis w/ simult. contractions); <i class="calibre3">Hypercontractile</i> (high amp contract.; Rx w/PPI, nitrates/CCB/PDEi, TCA)</p>
<p class="ol"><span class="sol">3.</span> <span class="underline">Minor motility disorders</span>: <i class="calibre3">Fragmented peristalsis; Hypomotility</i> (↓ amp of distal esoph contractions; seen in scleroderma, DM, hypothyroid.; Rx w/ underlying disorder &amp; w/ PPI)</p>
<p class="h">G<small class="calibre30">ASTROESOPHAGEAL</small> R<small class="calibre30">EFLUX</small> D<small class="calibre30">ISEASE</small> (GERD)</p>
<p class="h2a">Pathophysiology</p>
<p class="bl"><span class="sbl">•</span> ↑ acid exposure in esophagus, caused by ↑ transient LES relaxations. Worsened by ↑ intraabd pressure (eg, obesity, pregnancy), ↓ esophagogastric motility, hiatal hernia. Rarely caused by ↑ acid production except in ↑ secretory states (eg, Zollinger-Ellison)</p>
<p class="bl"><span class="sbl">•</span> Precipitants: supine position, fatty foods, caffeine, alcohol, cigarettes, CCB, pregnancy</p>
<p class="h2a"><a id="page_3-2" class="calibre1"></a>Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Esophageal: <b class="calibre4">heartburn</b>, atypical chest pain, regurgitation, water brash, dysphagia</p>
<p class="bl"><span class="sbl">•</span> Extraesophageal: <b class="calibre4">cough</b>, asthma (often poorly controlled), laryngitis, dental erosions</p>
<p class="h2a">Diagnosis <span class="s">(<i class="calibre3">Annals</i> 2015;163:ITC1; <i class="calibre3">Nat Rev Gastro Hepatol</i> 2016;13:501)</span></p>
<p class="bl"><span class="sbl">•</span> Clinical diagnosis based on sx and response to empiric trial of PPI (“PPI test”)</p>
<p class="bl"><span class="sbl">•</span> EGD: if (1) ∅ response to PPI; or if (2) <b class="calibre4"><i class="calibre3">alarm features</i>:</b> dysphagia, vomiting, ↓ wt, anemia</p>
<p class="bl"><span class="sbl">•</span> If dx uncertain &amp; EGD nl → esoph manometry w/ 24-h pH monitoring ± impedance to dx:</p>
<p class="bl1">“Nonerosive reflux disease”: no erosion, ulceration or Barrett’s; ½ abnl pH. Unpredictable response to PPI. Most will <i class="calibre3">not</i> progress to erosive esophagitis or Barrett’s.</p>
<p class="bl1">“Reflux hypersensitivity”: nl acid exposure on pH/impedance w/ symptom–reflux assoc.</p>
<p class="bl1">“Functional heartburn”: nl acid exposure on pH/impedance w/o symptom–reflux assoc.</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">World J Gastrointest Endosc</i> 2018;10:175)</span></p>
<p class="bl"><span class="sbl">•</span> Lifestyle: avoid precipitants, lose weight, avoid large &amp; late meals, elevate head of bed</p>
<p class="bl"><span class="sbl">•</span> Medical: PPI achieve relief in 80–90% of Pts; H2 blockers for intermittent sx</p>
<p class="bl"><span class="sbl">•</span> Refractory: confirm w/ pH testing (on PPI to assess need for ↑ Rx, or off PPI to verify dx).</p>
<p class="bl1">If acidic or sx correlate w/ reflux episodes: surgical fundoplication (emerging Rx: LES sphincter augmentation w/ radiofrequency, implantable magnetic or electrical devices)</p>
<p class="bl1">If nl pH or no sx correlation: Dx: ”functional heartburn”. Rx w/ TCA, SSRI or baclofen.</p>
<p class="h2a">Complications <span class="s">(<i class="calibre3">Gastro Clin NA</i> 2015;44:203; <i class="calibre3">Gastro</i> 2015;149:567 &amp; 1599)</span></p>
<p class="bl"><span class="sbl">•</span> Reflux esophagitis (erosions/ulcers above GE jxn), strictures (caused by chronic inflamm)</p>
<p class="bl"><span class="sbl">•</span> Barrett’s esoph. (BE): metaplastic columnar mucosa above GE jxn replaces squam epithel.</p>
<p class="bl1">Screen if chronic (&gt;5 y) and/or frequent GERD (≥1/wk) in ♂ w/ ≥2 risk factor for Barrett’s/esophageal adeno: &gt;50 y, white, hiatal hernia, central adiposity, smoking, FHx of Barrett’s/esophageal adeno. In ♂, consider only if multiple RFs. 0.1–0.3%/y risk of esoph adenocarcinoma, ↑ if ↑ dysplasia <span class="s1r">(<i class="calibre3">Am J Gastro</i> 2016;111:30)</span>.</p>
<p class="bl1">Mgmt: PPI. W/o dysplasia: surveillance EGD q3–5y. Low-grade dysplasia: EGD q12mo; possible endoscopic eradication. High-grade dysplasia: endoscopic eradication; consider chemoprophylaxis w/ high-dose PPI &amp; ASA <span class="s1r">(<i class="calibre3">Lancet</i> 2018;392:400)</span>.</p>
<p class="h">P<small class="calibre30">EPTIC</small> U<small class="calibre30">LCER</small> D<small class="calibre30">ISEASE</small> (PUD)</p>
<p class="h2a">Definition &amp; etiologies <span class="s">(<i class="calibre3">Lancet</i> 2017;390:613)</span></p>
<p class="bl"><span class="sbl">•</span> Ulcers (break in mucosal lining &gt;5 mm) &amp; erosions (&lt;5 mm) in stomach and duodenum</p>
<p class="bl"><span class="sbl">•</span> Principal risk factors: <i class="calibre3">H. pylori</i> infection &gt; NSAID/ASA use</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">H. pylori</i> infection:</b> causes ~60–70% of duodenal ulcers (DU) &amp; ~30–40% of gastric ulcers (GU). ~50% of world colonized w/ <i class="calibre3">H. pylori</i>, but only 5–10% will develop PUD.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ASA</b> &amp; <b class="calibre4">NSAIDs:</b> damage to mucosa caused by ↓ prostaglandin synthesis. Cause majority of non–<i class="calibre3">H. pylori</i>-related DU &amp; GU. Regular use a/w 5–6× ↑ odds of GIB.</p>
<p class="bl"><span class="sbl">•</span> Other: smoking, stress, excessive EtOH, gastric cancer/lymphoma, Crohn’s, viral infxn (eg, CMV/HSV in immunosupp), bisphosphonates, steroids (in combo w/ NSAIDs, but not risk factor alone); rarely gastrinoma (Zollinger-Ellison synd.), mastocytosis, idiopathic</p>
<p class="bl"><span class="sbl">•</span> Stress ulcer: risk factors = ICU &amp; coagulopathic, mech vent, h/o GIB, steroid use; Rx w/ PPI</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Epigastric gnawing abdominal pain:</b> relieved with food (DU) or worsened by food (GU)</p>
<p class="bl"><span class="sbl">•</span> Complications: UGIB, perforation &amp; penetration, gastric outlet obstruction</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Testing for <i class="calibre3">H. pylori:</i> stool Ag, urea breath testing (UBT) or EGD + rapid urease test (RUT) False ⊖ Ag, UBT, RUT if on abx, bismuth, PPI; ∴ stop prior to testing if possible Serology: ↓ utility, useful only to exclude infection in low prevalence areas (most of U.S.)</p>
<p class="bl"><span class="sbl">•</span> EGD (definitive dx): if fail empiric Rx or alarm features (see “GERD”); bx GU to r/o malig &amp; <i class="calibre3">H. pylori;</i> relook in 6–12 wk if &gt;2 cm, malig features, risk factors for gastric cancer (ie, ⊕ FHx, ⊕ <i class="calibre3">H. pylori</i>, atrophic gastritis, dysplasia/ metaplasia on bx, &gt;50 y), or sx persist</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Lancet</i> 2016;388:2355; <i class="calibre3">Gastro</i> 2016;151:51; <i class="calibre3">Gut</i> 2017;66:6; <i class="calibre3">AJG</i> 2017;112:212)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">If <i class="calibre3">H. pylori</i></b> ⊕ → <b class="calibre4">eradicate</b> (“test and treat”); if ⊖ → gastric acid suppression w/ PPI</p>
<p class="bl1">1<sup class="calibre15">st</sup> line: Quad. Rx: 14d x [MNZ + TCN + bismuth + PPI] or [MNZ + amox + clarith + PPI]</p>
<p class="bl1">Besides PUD, test &amp; Rx if: gastric MALT lymphoma, s/p resection for early gastric ca, FHx gastric ca, unexplained iron def. anemia, ITP, uninvestigated dyspepsia in Pt &lt;60 y, or when initiating long-term NSAIDs</p>
<p class="bl"><span class="sbl">•</span> “Test-of-cure”: 4 wk after Rx, off PPI x 1–2 wk. Use stool Ag, EGD + RUT or UBT.</p>
<p class="bl"><span class="sbl">•</span> Lifestyle changes: d/c smoking and probably EtOH; diet does not seem to play a role</p>
<p class="bl"><span class="sbl">•</span> Surgery: if refractory to med Rx (1<sup class="calibre15">st</sup> r/o NSAID use) or for complications (see above)</p>
<p class="h2a">GI prophylaxis in Pts taking ASA and/or NSAIDs <span class="s">(<i class="calibre3">JACC</i> 2016;67:1661)</span></p>
<p class="bl"><span class="sbl">•</span> PPI if h/o PUD/UGIB and either (a) also on clopidogrel or (b) ≥2 of the following: age &gt;60 y, steroids or dyspepsia; prior to start test &amp; Rx <i class="calibre3">H. pylori</i></p>
<p class="bl"><span class="sbl">•</span> Consider Δ non-selective NSAID to selective COX-2 inhibitor (↓ PUD &amp; UGIB but ↑ CV events) if low CV risk &amp; not on ASA</p>
<h2 class="ct"><a id="h40" class="calibre7"></a><a id="page_3-3" class="calibre7"></a><a href="part0002.html#rh46" class="calibre7">GASTROINTESTINAL BLEEDING</a></h2>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Intraluminal blood loss anywhere from the oropharynx to the anus</p>
<p class="bl"><span class="sbl">•</span> Classification: <b class="calibre4">upper</b> = above the ligament of Treitz; <b class="calibre4">lower</b> = below the ligament of Treitz</p>
<p class="bl"><span class="sbl">•</span> “Severe” GIB: defined as having associated shock, orthostatic hypotension, ↓ Hct by 6% (or ↓ Hb by 2 g/dL), or requiring transfusion ≥2U PRBCs. Requires hospitalization.</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hematemesis</b> = blood in vomitus (UGIB)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Coffee-ground emesis</b> = emesis of blood exposed to gastric acid (UGIB)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Melena</b> = black, tarry stools from digested blood (usually UGIB, but can be from R colon)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hematochezia</b> = bloody or maroon-colored stools (LGIB or rapid UGIB)</p>
<p class="h2a">Initial management</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Assess severity:</b> <i class="calibre3">VS including orthostatic</i> Δ<i class="calibre3">s, JVP.</i> Tachycardia (can be masked by βB use) suggests 10% volume loss, orthostatic hypotension 20% loss, shock &gt;30% loss. Scoring systems predict rebleeding &amp; mortality: AIMS65 &amp; Glasgow-Blatchford.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">History:</b> prior GIB, tempo of current bleed, specific bleeding manifestations (see above), other GI s/s (eg, abd pain, Δ in bowel habits, weight loss, N/V), NSAID/ASA or EtOH use, anticoag/antiplt drugs, h/o or risk factors for cirrhosis, radiation, prior GI or aortic surgery</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Physical exam:</b> localizable abd tenderness, peritoneal signs, masses, LAN, prior surgery,</p>
<p class="bl1">signs of liver disease (hepatosplenomegaly, ascites, jaundice, telangiectasias), rectal exam: masses, hemorrhoids, anal fissures, stool appearance, color</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Resuscitation:</b> placement of 2 large-bore (18-gauge or larger) intravenous lines Volume replacement: NS or LR to achieve normal VS, UOP, &amp; mental status</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lab studies: Hct</b> <span class="s1r">(<i class="calibre3">may be normal</i> in first 24 h of acute GIB before equilibration)</span></p>
<p class="bl1">2–3% → 500 mL blood loss; low MCV → Fe deficient and chronic blood loss; <b class="calibre4">plt</b>, <b class="calibre4">PT</b>, <b class="calibre4">PTT;</b> BUN/Cr (ratio &gt;36 in UGIB b/c GI resorption of blood ± prerenal azotemia); LFTs</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transfuse:</b> type &amp; cross; use O-neg if emerg; for UGIB (esp. w/ portal HTN) transfuse w/ more restrictive Hb goal (eg, 7 g/dL) or &gt;8 g/dL if CAD <span class="s1r">(<i class="calibre3">JAMA</i> 2016;316:2025)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Reverse coagulopathy:</b> consider FFP to normalize PT; plts to keep count &gt;50,000</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Triage:</b> alert endoscopist. Consider ICU if unstable VS or poor end organ perfusion.</p>
<p class="bl1">Intubation for: emergent EGD, ongoing hematemesis, shock, poor resp status, Δ MS</p>
<p class="bl1">? OutPt management if SBP ≥110, HR &lt;100, Hb ≥13 (♂) or ≥12 (♀), BUN &lt;18, ∅ melena, syncope, heart failure, liver disease <span class="s1r">(<i class="calibre3">Clin Gastro Hepatol</i> 2015;13:115)</span></p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> UGIB: <b class="calibre4">EGD</b> w/in 24 h. If severe bleed, ↑ Dx/Rx yield by gastric lavage and <b class="calibre4">erythro 250 mg IV 30 min prior to endoscopy</b> to clear stomach contents <span class="s1r">(<i class="calibre3">Am J Gastro</i> 2006;101:1211)</span>.</p>
<p class="bl"><span class="sbl">•</span> LGIB: <b class="calibre4">colonoscopy</b> (identifies cause in &gt;70%); if severe, colo w/in 12 h → consider rapid purge w/ PEG solution (6–8 L over 4–6 h). If hematochezia a/w orthostasis, concern for brisk UGIB → <i class="calibre3">exclude UGIB w/ EGD first.</i> Push enteroscopy, anoscopy, capsule endoscopy in combo w/ urgent colo results in dx &gt;95% of cases <span class="s1r">(<i class="calibre3">GI Endo</i> 2015;81:889)</span>.</p>
<p class="bl"><span class="sbl">•</span> Imaging: if too unstable for endo or recurrent bleeding, can then → IR procedure or surgery</p>
<p class="bl1"><b class="calibre4">tagged RBC scan:</b> can identify general luminal location if bleeding rate ≥0.04 mL/min</p>
<p class="bl1"><b class="calibre4">CT angiography:</b> faster to obtain than RBC scan, detects bleeding ≥0.3 mL/min</p>
<p class="bl1"><b class="calibre4">arteriography:</b> can localize exact vessel if bleeding rates ≥0.5 mL/min, <i class="calibre3">allows for IR Rx</i></p>
<p class="bl"><span class="sbl">•</span> Emergent exploratory laparotomy (last resort) if no localization and life-threatening bleed</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre33"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabhead">Etiology UGIB</p></td>
<td class="bg1-b"><p class="tabhead">Comment &amp; Treatment</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4">PUD</b> (20–67%)</p>
<p class="tab">(<span class="tfont"><i class="calibre3">Am J Gastro</i> 2014;109:1005; <span class="calibre19"><i class="calibre3">NEJM</i></span> 2016;374:2367; <span class="calibre19"><i class="calibre3">Br J Clin Pharm</i></span> 2017;83:1619</span>)</p>
<p class="tab">See “PUD”</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Treatment:</i> <b class="calibre4">PPI:</b> 40 mg PO or IV BID. ? Octreotide if suspect varices.</p>
<p class="tabh"><b class="calibre4">Endoscopic therapy:</b> epi inj + bipolar cautery or hemoclip. Bx for ? <i class="calibre3">H. pylori</i> and treat if ⊕.</p>
<p class="tabh"><i class="calibre3">High-risk (for rebleeding) ulcer</i>: arterial spurting, adherent clot, visible vessel. Endo Rx, IV PPI × 72 h post EGD, then Δ to high-dose oral PPI. If fail, arteriography w/ embolization; surgery (last resort).</p>
<p class="tabh"><i class="calibre3">Intermediate-risk ulcer</i>: oozing, in o/w stable Pt. Endo Rx, can Δ to oral PPI after EGD and observe 24–48 h.</p>
<p class="tabh"><i class="calibre3">Low-risk ulcer:</i> clean-based or flat. Oral PPI &amp; ? discharge.</p>
<p class="tabh">Hold anticoag &amp; antiplatelet Rx until hemostasis; can resume after hemostasis &amp; PPI on board (<span class="tfont"><i class="calibre3">Endoscopy</i> 2015;47:a1</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4">Erosive gastropathy</b></p>
<p class="tab">(4–31%)</p></td>
<td class="bg0-b"><p class="tab">Precipitants: NSAIDs, ASA, EtOH, cocaine, gut ischemia, XRT</p>
<p class="tabh">Stress-related mucosal injury in ICU Pts. Risk factors include severe coagulopathy, mech vent &gt;48 h, high-dose glucocorticoids</p>
<p class="tab">Treatment: high-dose PPI</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4">Erosive esopha-gitis</b> (5–18%)</p></td>
<td class="bg0-b"><p class="tabh">Risk factors: cirrhosis, anticoagulation, critical illness. Rx offending cause + high-dose PPI; repeat EGD later to r/o underling Barrett’s.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><a id="page_3-4" class="calibre1"></a><p class="tab"><b class="calibre4">Esophageal or gastric varices</b> (4–20%)</p>
<p class="tab">(<span class="tfont"><i class="calibre3">Clin Gastro Hepatol</i> 2015;13:2109; <span class="calibre19"><i class="calibre3">J Gastro Hepatol</i></span> 2016;31:1519; <span class="calibre19"><i class="calibre3">Hep</i></span> 2017;65:310</span>)</p>
<p class="tab">See “Cirrhosis”</p></td>
<td class="bg0-b"><p class="tab">2° to portal HTN. If isolated gastric → r/o splenic vein thrombosis.</p>
<p class="tab"><i class="calibre3"><span class="underline">Pharmacologic</span></i></p>
<p class="tabh">Start <b class="calibre4">octreotide</b> pending EGD if suspect varices: 50 µg IVB → 50 µg/h (84% success). Rx for 2–5 d, but most benefit w/in 24–48 h.</p>
<p class="tabh">Abx: 20% cirrhotics p/w GIB have infxn, &amp; ~50% develop infxn during hospitalization; Ppx w/ IV CTX, cipro, or levoflox × 7 d</p>
<p class="tab"><i class="calibre3"><span class="underline">Nonpharmacologic</span></i></p>
<p class="tabh">Esophageal varices: <b class="calibre4">endoscopic band ligation</b> (&gt;90% success). Covered esophageal stent placement or balloon tamponade if refractory as bridge to TIPS (consider early espec. if Child-Pugh C).</p>
<p class="tabh">Gastric varices: arteriography w/ coiling, or if available, endoscopic injection of cyanoacrylate (glue). If refractory: TIPS or balloon-retrograde transvenous obliteration.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">Portal HTN gastropathy</p></td>
<td class="bg0-b"><p class="tab">↑ portal venous pressure → ectatic vessels, hyperemia in prox. gastric body. No endoscopic option; Rx portal HTN (octreotide), βB.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="4"><p class="tab"><b class="calibre4">Vascular (2–8%)</b></p></td>
<td class="bg0-br"><p class="tab">Angioectasia AVMs, HHT (see below)</p></td>
<td class="bg0-b"><p class="tab">AVMs congenital. Angioectasia (ectatic submucosal vessels) a/w ↑ age, CKD, cirrhosis, CTD, severe CV dis. <i class="calibre3">Heyde syndrome:</i> GIB due to angioectasias + aortic stenosis. Endo Rx.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Dieulafoy’s lesion</p></td>
<td class="bg0-b"><p class="tab">Large (1–3 mm) submucosal artery protruding through fundal mucosa → sudden, massive UGIB. <i class="calibre3">Difficult to identify.</i> Endo Rx.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Gastric antral vasc. ectasia (GAVE)</p></td>
<td class="bg0-b"><p class="tab">“<i class="calibre3">Watermelon stomach</i>”; ectatic gastric vessels, often a/w cirrhosis, CTD, typically older ♂. Rx w/ EGD w/ thermal hemostasis, repeat q4–8wk to eradicate lesions. TIPS does <i class="calibre3">not</i> improve outcomes.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Aortoenteric fistula</p></td>
<td class="bg0-b"><p class="tab">AAA or aortic graft erodes into 3<sup class="calibre35">rd</sup> portion of duodenum. P/w “herald bleed”; if suspected, diagnose by endoscopy or CT.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">Malignancy (2–8%)</p></td>
<td class="bg0-b"><p class="tab">Endoscopic hemostasis of mass temporizing measure till cancer Rx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">Mallory-Weiss tear (4–12%)</p></td>
<td class="bg0-b"><p class="tab">GE jxn lacerations due to vomiting → ↑ intraabd pressure &amp; shearing effect. Can self-resolve w/o endo Rx. Rx w/ antiemetics, PPI.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab">Cameron’s lesions</p></td>
<td class="bg0-b"><p class="tab">Linear erosions in hiatal hernia due to mech trauma of diaphragm</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r" colspan="2"><p class="tab">Post-sphincter-otomy bleeding</p></td>
<td class="bg"><p class="tab">Occurs in ~2% of ERCP w/ sphincterotomy; ↑ risk w/ more complic. procedure. Bleeding into duodenum. Rx w/ endo hemostasis.</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">GI Endosc Clin N Am</i> 2015;25:415)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead">Etiology LGIB</p></td>
<td class="bg1-b"><p class="tabhead">Comment &amp; Treatment <span class="tfont1">(<i class="calibre3">NEJM</i> 2017;376:1054)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Diverticular bleed</b> (30%)</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Pathophysiology:</i> Intimal thickening and medial thinning of vasa recta as they course over dome of diverticulum → weakening of vascular wall → arterial rupture. Diverticula more common in left colon; but <i class="calibre3">bleeding diverticula more often in right colon.</i></p>
<p class="tabh"><i class="calibre3">Clinical:</i> older, ASA/NSAIDs, usually painless hematochezia ± abd cramping</p>
<p class="tabh"><i class="calibre3">Treatment:</i> Usually stops spont. (~75%) but may take hrs–days; ~20% recur. Can perform endo hemostasis w/ epi injections ± electrocautery, hemoclip, banding. Intra-arterial vasopressin or embo. Surgery (partial colectomy) last resort.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Polyp/Tumor (20%)</p></td>
<td class="bg0-b"><p class="tab">Typically slow ooze, p/w fatigue, weight loss, iron deficiency anemia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Colitis (20%)</p></td>
<td class="bg0-b"><p class="tab">Infectious (see “Acute Diarrhea”), IBD, ischemic colitis, XRT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Anorectal disorders (20%)</p></td>
<td class="bg0-b"><p class="tab">Internal, external hemorrhoids; anal fissures, rectal ulcers, rectal varices (Rx by ↓ portal venous pressure in cirrhotics), XRT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Vascular (&lt;10%)</p></td>
<td class="bg0-b"><p class="tab">Angioectasia &amp; AVMs (see above). <i class="calibre3">Hereditary hemorrhagic</i></p>
<p class="tab"><i class="calibre3">telangiectasia (Weber-Osler-Rendu):</i> diffuse AVMs, telangiectasias</p>
<p class="tab">throughout GI mucosa (also involve lips, oral mucosa, fingertips).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Meckel’s diverticulum</p></td>
<td class="bg"><p class="tab">Congenital blind intestinal pouch due to incomplete obliteration of vitelline duct. <span class="underline">2</span>% of pop, w/in <span class="underline">2′</span> of IC valve, <span class="underline">2″</span> long, ♂:♀ <span class="underline">2</span>:1, often present age 2 y (but can cause obscure GIB in adults). Dx w/ <sup class="calibre35">99m</sup>Tc-pertechnetate scintigraphy. Rx w/ angioembo, surgical resection.</p></td>
</tr>
</table>
<p class="h2a">Obscure GIB <span class="s">(<i class="calibre3">Am J Gastro</i> 2015;110:1265; <i class="calibre3">Gastro</i> 2017;152:497)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Definition:</b> continued bleeding (melena, hematochezia) despite ⊖ EGD &amp; colo; 5% of GIB</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Etiologies:</b> Dieulafoy’s lesion, GAVE, small bowel angiodysplasia, ulcer or cancer, Crohn’s disease, aortoenteric fistula, Meckel’s diverticulum, hemobilia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diagnosis:</b> repeat EGD w/ push enteroscopy/colonoscopy when bleeding is active</p>
<p class="bl1">If ⊖, video capsule to evaluate small intestine <span class="s1r">(<i class="calibre3">GIE</i> 2015;81:889)</span></p>
<p class="bl1">If still ⊖, consider <sup class="calibre15">99m</sup>Tc-pertechnetate scan (“Meckel’s scan”), enteroscopy (single-balloon, double-balloon or spiral), tagged RBC scan and arteriography</p>
<h2 class="ct"><a id="h41" class="calibre7"></a><a id="page_3-5" class="calibre7"></a><a href="part0002.html#rh47" class="calibre7">DIARRHEA</a></h2>
<p class="h">A<small class="calibre30">CUTE</small> D<small class="calibre30">IARRHEA</small> (&lt;4 <small class="calibre30">WEEKS</small>’ <small class="calibre30">DURATION</small>)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre33"/>
<col class="calibre28"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3">
<p class="tab"><b class="calibre4">Acute Infectious Etiologies</b> <span class="tfont">(<i class="calibre3">NEJM</i> 2014;370:1532; <span class="calibre19"><i class="calibre3">JAMA</i></span> 2015;313:71; <span class="calibre19"><i class="calibre3">CDC Yellow Book</i></span> 2018)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4"><span class="underline">Noninflammatory</span></b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Predom. disruption small intestine absorp. &amp; secretion. Voluminous diarrhea, N/V.</b> ⊖ <b class="calibre4">Fecal WBC &amp; FOB.</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4">Preformed toxin</b></p></td>
<td class="bg0-b"><p class="tab">“Food poisoning,” &lt;24 h dur. <i class="calibre3">S. aureus</i> (meats &amp; dairy),</p>
<p class="tab"><i class="calibre3">B. cereus</i> (fried rice), <i class="calibre3">C. perfringens</i> (rewarmed meats).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" rowspan="2"><p class="tab"><b class="calibre4">Viral</b> (<span class="tfont"><i class="calibre3">Lancet</i></span> 2018; 392:175)</p></td>
<td class="bg0-br"><p class="tab">Rotavirus</p></td>
<td class="bg0-b"><p class="tab">Outbreak person to person (PTP), daycare; lasts 4–8 d.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Norovirus</p></td>
<td class="bg0-b"><p class="tab">~50% of all diarrhea. Winter outbreaks; PTP &amp; food/water;</p>
<p class="tab">no immunity. Lasts 1–3 d. Vomiting prominent.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" rowspan="2"><p class="tab"><b class="calibre4">Bacterial</b></p></td>
<td class="bg0-br"><p class="tab"><i class="calibre3">E. coli</i> (toxigenic)</p></td>
<td class="bg0-b"><p class="tab">&gt;50% of traveler’s diarrhea; cholera-like toxin; &lt;7 d.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Vibrio cholerae</i></p></td>
<td class="bg0-b"><p class="tab">Contam H<sub class="calibre13">2</sub>O, fish, shellfish; “rice water” stools w/ severe dehydration &amp; electrolyte depletion.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Parasitic</b></p></td>
<td class="bg0-br"><p class="tab"><i class="calibre3">Giardia</i></p></td>
<td class="bg0-b"><p class="tab">Streams/outdoor sports, travel, outbreaks. Bloating.</p>
<p class="tab">Acute (profuse, watery) → chronic (greasy, malodorous).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" rowspan="2"><p class="tab">(± malab for mos after Rx)</p></td>
<td class="bg0-br"><p class="tab"><i class="calibre3">Cryptosporidia</i></p></td>
<td class="bg0-b"><p class="tab">In soil; water-borne outbreak; usually self-limited, can → chronic infxn if immunosupp. Abd pain (80%), fever (40%).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Cyclospora</i></p></td>
<td class="bg0-b"><p class="tab">Contaminated produce</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4"><span class="underline">Inflammatory</span></b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Predom. colonic invasion. Small-vol diarrhea. LLQ cramps, tenesmus, fever, typically</b> ⊕ <b class="calibre4">fecal WBC or FOB.</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" rowspan="8"><p class="tab"><b class="calibre4">Bacterial</b></p></td>
<td class="bg0-br"><p class="tab"><i class="calibre3">Campylobacter</i></p></td>
<td class="bg0-b"><p class="tab">Undercooked poultry, unpasteurized milk; carried by puppies &amp; kittens. Prodrome w/ abd pain, “pseudoappendicitis”; c/b GBS, reactive arthritis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Salmonella</i></p>
<p class="tab">(nontyphoidal)</p></td>
<td class="bg0-b"><p class="tab">Eggs, poultry, milk, hamsters. Bacteremia in 5–10%. 10–33% of bacteremic Pts &gt;50 y may develop aortitis.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Shigella</i></p></td>
<td class="bg0-b"><p class="tab">Abrupt onset; gross blood &amp; pus in stool; ↑↑ WBC.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">E. coli</i> (O157:H7 &amp; inv/hemorrhagic</p>
<p class="tab">non-O157:H7)</p></td>
<td class="bg0-b"><p class="tab">Undercooked beef, unpasteurized milk, raw produce; PTP.</p>
<p class="tab">O157 &amp; non-O157 sp. (40%) produce <i class="calibre3">Shiga</i> toxin → HUS</p>
<p class="tab">(typically in children). Gross blood in stool.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">C. difficile</i></p></td>
<td class="bg0-b"><p class="tab">See later</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Vibrio parahaem.</i></p></td>
<td class="bg0-b"><p class="tab">Undercooked seafood</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Salmonella typhi</i></p></td>
<td class="bg0-b"><p class="tab">Travel to Asia, Africa, South America. Systemic toxicity, relative bradycardia, rose spot rash, ileus → “pea-soup” diarrhea, bacteremia.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Other</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Yersinia:</i> undercooked pork; unpasteurized milk, abd pain → “pseudoappendicitis” (aka mesenteric adenitis)</p>
<p class="tab"><i class="calibre3">Aeromonas, Plesiomonas, Listeria</i> (meats &amp; cheeses)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Parasitic</b></p></td>
<td class="bg0-br"><p class="tab"><i class="calibre3">E. histolytica</i></p></td>
<td class="bg0-b"><p class="tab">Contaminated food/water, travel (rare in U.S.); liver abscess</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Viral</b></p></td>
<td class="bg0-r"><p class="tab">CMV</p></td>
<td class="bg"><p class="tab">Immunosuppressed; dx by shell vial cx of colon bx</p></td>
</tr>
</table>
<p class="h2a">Evaluation <span class="s">(<i class="calibre3">NEJM</i> 2014;370:1532; <i class="calibre3">Digestion</i> 2017;95:293; <i class="calibre3">PLOS One</i> 2017;12:11)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ddx:</b> hyperthyroid, adrenal insufficiency, meds (abx, antacids, checkpt inhibitors), appendicitis, diverticulitis, 1st presentation of primary bowel disorder (eg, IBD, celiac)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">History:</b> stool freq, blood, abd pain, duration of sxs [~1 wk for viral &amp; bacterial (except <i class="calibre3">C. diff</i>), &gt;1 wk for parasitic], travel, food, recent abx, immunocompromise</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PEx:</b> vol depletion (VS, UOP, axillae, skin turgor, MS), fever, abd tenderness, ileus, rash</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Laboratory:</b> ✔ calprotectin, stool cx, BCx, lytes, <i class="calibre3">C. diff</i> (if recent hosp/abx), stool O&amp;P (if &gt;10 d, travel to endemic area, exposure to unpurified H<sub class="calibre8">2</sub>O, community outbreak, daycare, HIV ⊕ or MSM); ± stool ELISAs (viruses, <i class="calibre3">Crypto</i>, <i class="calibre3">Giardia</i>), serologies (<i class="calibre3">E. histolytica</i>); PCR available (but high ⊕ rate &amp; unclear if true vs colonized; consider if immunocompromised)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Imaging/endoscopy:</b> consider if <b class="calibre4"><i class="calibre3">warning signs (WS)</i></b> of fever, severe abd pain, blood or pus in stool, &gt;6 stools/d, severe dehydration, immunosupp, elderly, duration &gt;7 d, hosp-acquired. CT/KUB if ? toxic megacolon; sig/colo if immunosupp or cx ⊖</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Am J Gastro</i> 2016;111:602; <i class="calibre3">Clin Infect Dis</i> 2017;65:e45)</span></p>
<p class="bl"><span class="sbl">•</span> If no <b class="calibre4">WS</b>, nl PO intake → supportive: hydrate, loperamide, bismuth subsalicylate (∅ antichol)</p>
<p class="bl"><span class="sbl">•</span> If mod. dehydration: 50–200 mL/kg/d of oral solution or Gatorade, etc. If severe: IV fluids.</p>
<p class="bl"><span class="sbl">•</span> If suspect traveler’s diarrhea → FQ, rifaximin, or rifamycin; if suspect protozoal → flagyl or nitazoxanide</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Empiric</i> abx for non–<i class="calibre3">C. diff inflammatory</i> diarrhea reasonable: FQ × 5–7 d</p>
<p class="bl1">Abx rec for <i class="calibre3">Shigella</i>, cholera, <i class="calibre3">Giardia</i>, amebiasis, <i class="calibre3">Salmonella</i> if Pt &gt;50 y or immunosupp or hospitalized, ? <i class="calibre3">Campylobacter</i> (if w/in 4 d of sx onset)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Avoid</i> abx if suspect <i class="calibre3">E. coli</i> O157:H7 (exposure hx, gross blood) as may ↑ risk of HUS</p>
<p class="h"><a id="page_3-6" class="calibre7"></a>C<small class="calibre30">LOSTRIDIOIDES</small> D<small class="calibre30">IFFICILE</small> I<small class="calibre30">NFECTION</small> (CDI)</p>
<p class="h2a">Pathogenesis &amp; epidemiology <span class="s">(<i class="calibre3">NEJM</i> 2015;372:825)</span></p>
<p class="bl"><span class="sbl">•</span> Ingestion of <i class="calibre3">C. diff</i> spores → colonization when colonic flora Δd by abx or chemo → release of toxin A/B → colonic mucosal necrosis &amp; inflammation → pseudomembranes</p>
<p class="bl"><span class="sbl">•</span> Most frequently reported nosocomial infxn; community-acquired infxn may account for up to <sup class="calibre15">1</sup>/<sub class="calibre8">3</sub> of new cases. Associated w/ <i class="calibre3">any</i> abx (esp. β-lactams, clinda, quinolones).</p>
<p class="bl"><span class="sbl">•</span> Elderly, immunocompromised, and IBD Pts can develop CDI w/o recent abx exposure</p>
<p class="h2a">Clinical manifestations <span class="s2">(a spectrum of disease)</span></p>
<p class="bl"><span class="sbl">•</span> Asx colonization: &lt;3% healthy adults; ~20% in hospitalized patients on antibiotics</p>
<p class="bl"><span class="sbl">•</span> Acute watery diarrhea (occ bloody) ± mucus, often w/ lower abd pain, fever, ↑↑↑ WBC</p>
<p class="bl"><span class="sbl">•</span> Pseudomembranous colitis: above sx + pseudomembranes + bowel wall thickening</p>
<p class="bl"><span class="sbl">•</span> Fulminant colitis (2–3%): <b class="calibre4">toxic megacolon</b> (colonic atony/absence of BMs, colon dilatation ≥6 cm on KUB, systemic toxicity) and/or bowel perforation</p>
<p class="h2a">Diagnosis <span class="s">(<i class="calibre3">Ann Intern Med</i> 2018;169:49)</span></p>
<p class="bl"><span class="sbl">•</span> Only test if <i class="calibre3">symptomatic</i> (diarrhea, s/s of colitis); test <i class="calibre3">liquid</i> stool (unless concern for ileus)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stool toxin immunoassay</b> (high Sp) + <b class="calibre4">glutamate dehydrogenase (GDH)</b> (high Se)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stool PCR:</b> has ↑ Se, but ⊕ if colonized in absence of active infxn; should not necessarily Rx if ⊕ PCR w/ neg toxin assay <span class="s1r">(<i class="calibre3">JAMA IM</i> 2015;175;1792)</span></p>
<p class="bl"><span class="sbl">•</span> Obtain CT abdomen/pelvis if suspect complications (toxic megacolon). Consider flex sig if dx uncertain and/or evidence of no improvement on standard Rx.</p>
<p class="h2a">Initial treatment <span class="s">(<i class="calibre3">CID</i> 2018;66:48)</span></p>
<p class="bl"><span class="sbl">•</span> If possible, d/c abx ASAP; stop antimotility agents &amp; cholestyramine if using (binds vanco)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mild-mod:</b> vanco 125 mg PO q6h or fidaxomicin 200 mg BID × 10 d preferred over MNZ</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Severe</b> (any of the following: &gt;12 BM/d, Temp &gt;103°F, WBC &gt;25, HoTN, ICU care required, ileus): vanco 500 mg PO (or PR) q6h + MNZ 500 mg IV q8h</p>
<p class="bl"><span class="sbl">•</span> If worsening (ileus, ↑ WBC, ↑ lactate, shock, toxic megacolon, peritonitis): abd CT &amp; <b class="calibre4">urgent surgical consult</b> re: subtotal colectomy (? diverting loop ileostomy or colonic lavage)</p>
<p class="bl"><span class="sbl">•</span> If need to cont abx, cont <i class="calibre3">C. diff.</i> Rx for ≥7 d post-abx cessation <i class="calibre3">(Am J Gastro</i> 2016;111:1834)</p>
<p class="bl"><span class="sbl">•</span> Stool carriage may persist 3–6 wk postcessation of sx &amp; should not trigger further Rx (retesting for <i class="calibre3">C. diff</i> of limited utility during this time)</p>
<p class="h2a">Recurrent infection <span class="s2">(</span>1<span class="s2">5–30% risk after d/c of abx, most w/in 2 wk of stopping abx)</span></p>
<p class="bl"><span class="sbl">•</span> 1st recurrence: vanco 125 mg PO q6h × 10–14 d or fidaxomicin 200 mg PO bid × 10 d</p>
<p class="bl"><span class="sbl">•</span> Subsequent recurrences: vanco PO pulse → taper. Consult ID physician. Fecal microbial transplant <span class="s1r">(<i class="calibre3">JAMA</i> 2017;318:1985; <i class="calibre3">CID</i> 2018;66:1)</span> or fidaxomicin (200 mg bid × 10 d).</p>
<p class="bl"><span class="sbl">•</span> Prevention<b class="calibre4">:</b> <i class="calibre3">vanco</i> 125–250 mg PO BID ↓ risk of recurrence 27% → 4% <span class="s1r">(<i class="calibre3">CID</i> 2016;65:651)</span>; consider for Pts needing abx w/ h/o severe or recurrent CDI. <i class="calibre3">Bezlotoxumab</i> (mAb that binds toxin B) ↓ risk of recurrence in adults receiving <i class="calibre3">C. diff</i> Rx &amp; at high risk of recurrence <span class="s1r">(<i class="calibre3">NEJM</i> 2017; 376:305)</span>.</p>
<p class="h">C<small class="calibre30">HRONIC</small> D<small class="calibre30">IARRHEA</small> <span class="s1">(&gt;4 <small class="calibre23">WK</small>; <i class="calibre22">JAMA</i> 2016;315:2712)</span></p>
<p class="h2a">General evaluation</p>
<p class="bl"><span class="sbl">•</span> Clinically can be organized into <i class="calibre3">watery</i>, <i class="calibre3">fatty</i>, or <i class="calibre3">inflammatory stools</i></p>
<p class="bl"><span class="sbl">•</span> Additional hx: timing (freq, relation to meals; <i class="calibre3">nocturnal diarrhea</i> a/w organic causes like IBD rather than IBS), abd pain, wt loss, prior surg, chemo/XRT, diet (incl caffeine or poorly absorbed carbs/sugars), infectious sxs, immunocompromise, travel, laxative use, etc.</p>
<p class="bl"><span class="sbl">•</span> Hx offending meds: PPI, colchicine, abx, H2RA, SSRIs, ARBs, NSAIDs, chemo, caffeine</p>
<p class="bl"><span class="sbl">•</span> PEx: gen appearance (BMI), signs of systemic disease, surgical scars, rectal tone/DRE</p>
<p class="bl"><span class="sbl">•</span> Lab testing: CBC, metabolic profile, alb, TSH, Fe studies, ESR; <i class="calibre3">see under each category</i></p>
<p class="bl"><span class="sbl">•</span> Imaging/endoscopy: colonoscopy for chronic diarrhea of unknown cause. Abd CT/MRI usually warranted if systemic problem suspected.</p>
<p class="h2a">Osmotic <span class="s2">(watery;</span> ⊖<span class="s2"> fecal fat,</span> ↑<span class="s2"> osmotic gap,</span> ↓<span class="s2"> diarrhea with fasting)</span></p>
<p class="bl"><span class="sbl">•</span> Caused by ingestion of poorly absorbed cations/anions (Mg, sulfate, phos; found in laxatives) or poorly absorbed sugars (eg, mannitol, sorbitol; found in chewing gum; or lactose if lactose intolerant). <i class="calibre3">Diarrhea resolves w/ cessation of offending substance.</i></p>
<p class="bl"><span class="sbl">•</span> Dx: ↑ <b class="calibre4">stool osmotic gap</b> (see Figure); stool pH &lt;6 if unabsorbed carbohydrates</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lactose intolerance</b> (75% nonwhites &amp; 25% whites lactase-deficient): can be acquired after gastroenteritis, med illness, GI surg. Clin: bloating, flatulence, discomfort, diarrhea. Dx: H+ breath test or empiric lactose-free diet. Rx: lactose-free diet &amp; lactase tablets.</p>
<p class="h2a">Secretory <span class="s2">(watery; normal osmotic gap, no</span> Δ <span class="s2">diarrhea w/ fasting, often nocturnal diarrhea)</span></p>
<p class="bl"><span class="sbl">•</span> Caused by secretion of anions or K+ into lumen or inhib of Na absorption → ↑ H<sub class="calibre8">2</sub>O in stool. Most commonly caused by bacterial toxins from <b class="calibre4">infxn</b> (see above). Other causes:</p>
<p class="bl"><a id="page_3-7" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Endocrine:</b> Addison’s, VIPoma, carcinoid, Zollinger-Ellison, mastocytosis, hyperthyroid (↑ motility). ✔ serum peptide levels (eg, gastrin, calcitonin, VIP) &amp; urinary histamine.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">GI neoplasm:</b> carcinoma, lymphoma, villous adenoma</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Microscopic colitis:</b> common cause of chronic diarrhea w/ obscure origin. Often seen in middle-aged women w/ autoimmune disorders. NSAIDs, SSRIs, PPIs notable triggers. Grossly nl on colo but bx shows lymphocytic &amp; plasmacytic infiltration of mucosa ± thickened submucosal collagen. Rx: antidiarrheals, cholestyramine, bismuth, budesonide; consider anti-TNFs if refractory.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bile acid-induced diarrhea:</b> ileal resection or disease (eg, Crohn’s)→ bile acids in colon → electrolyte &amp; H<sub class="calibre8">2</sub>O secretion. Rx w/ empiric bile-acid binders (eg, cholestyramine).</p>
<p class="h2a">Fxnal/IBS <span class="s2">(watery; normal osmotic gap,</span> ↓<span class="s2"> diarrhea with fasting): see “Dysmotility”</span></p>
<p class="h2a">Malabsorption<span class="s2"> (fatty;</span> ↑<span class="s2"> fecal fat,</span> ↑<span class="s2"> osmotic gap,</span> ↓<span class="s2"> diarrhea w/ fasting)</span></p>
<p class="bl"><span class="sbl">•</span> Defective mucosal absorption of nutrients b/c Δs in: mucosal surface (surgical resection) or gen. mucosal dis. (celiac, IBD). Bloating, foul-smelling, floating stools (steatorrhea).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Celiac disease</b> <span class="s1r">(<i class="calibre3">JAMA</i> 2017;318:647; <i class="calibre3">Lancet</i> 2018;391:70)</span></p>
<p class="bl1">Immune rxn in genetically predisposed Pts (~1% pop) to gliadin, a component of gluten (wheat protein) → small bowel inflammatory infiltrate → impaired absorption</p>
<p class="bl1">Other s/s: Fe/folate defic anemia; osteoporosis; dermatitis herpetiformis; ↑ AST/ALT</p>
<p class="bl1">Dx: IgA anti-tissue transglutaminase Ab (most Se), IgA anti-deaminated gliadin peptide Ab; IgA α-endomysial Ab. Duodenal bx to confirm dx (blunted villi, crypt hyperplasia, inflamm infiltrate) but may not be necessary if serology ⊕ and Pt sx. HLA-DQ2/Q8 testing useful for high ⊖ predictive value if ⊖ serologies already on gluten-free diet.</p>
<p class="bl1">Rx: gluten-free diet; 7–30% do not respond to diet → ? wrong dx or noncompliant</p>
<p class="bl1">Complic: ~5% refractory sx, risk of T-cell lymphoma and small bowel adenocarcinoma</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Whipple’s disease:</b> infxn w/ <i class="calibre3">T. whipplei</i> <span class="s1r">(<i class="calibre3">Lancet</i> 2016;16:13)</span></p>
<p class="bl1">Other s/s: fever, LAN, edema, arthritis, CNS Δs, gray-brown skin pigmentation, AI &amp; MS, oculomasticatory myorhythmia (eye oscillations + mastication muscle contract).</p>
<p class="bl1">Dx: bx/path, IHC, PCR. Rx: PCN + streptomycin or 3<sup class="calibre15">rd</sup>-gen ceph × 10–14 d → Bactrim ≥1 y.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Small intestinal bacterial overgrowth</b> (SIBO): colonic bacteria in SI → steatorrhea, B12/Fe defic, protein-losing enteropathy. A/w dysmotility (DM neuropathy, scleroderma), Δ’d anatomy (Crohn’s, surgery, fistulae), immune deficiency, celiac, CF. Dx w/ H<sup class="calibre15">+</sup> or <sup class="calibre15">1</sup><sup class="calibre15">4</sup>C-xylose breath testing or empiric abx. Rx w/ 7–10 d abx (eg, rifaximin, MNZ, FQ).</p>
<p class="bl"><span class="sbl">•</span> Other: s/p short bowel resection (short bowel syndrome), chronic mesenteric ischemia, eosinophilic gastroenteritis, intestinal lymphoma, tropical sprue, <i class="calibre3">Giardia</i> infection</p>
<p class="h2a">Maldigestion <span class="s2">(fatty;</span> ↑<span class="s2"> fecal fat,</span> ↑<span class="s2"> osmotic gap,</span> ↓<span class="s2"> diarrhea w/ fasting)</span></p>
<p class="bl"><span class="sbl">•</span> Defective intraluminal hydrolysis of nutrients, typ. 2/2 pancreatic/hepatobiliary pathology</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pancreatic insufficiency:</b> most commonly from chronic pancreatitis or pancreatic cancer. Test w/ stool elastase, chymotrypsin levels, or empiric pancreatic enzyme replacement.</p>
<p class="bl"><span class="sbl">•</span> ↓ <b class="calibre4">bile acids</b> due to ↓ synthesis (cirrhosis), cholestasis (PBC), or s/p ileal resection. Test w/ empiric bile acid replacement therapy.</p>
<p class="h2a">Inflammatory <span class="s2">(</span>⊕<span class="s2"> fecal WBC, lactoferrin, or calprotectin;</span> ⊕<span class="s2"> FOB; fever, abd pain)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infections:</b> chronic <i class="calibre3">C. diff</i>, <i class="calibre3">Entamoeba histolytica</i>, <i class="calibre3">Yersinia</i>, CMV, TB especially in immunocompromised hosts. CMV, <i class="calibre3">C. diff</i> notorious for causing exacerbations of IBD.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Inflammatory bowel disease</b> (Crohn’s, UC)</p>
<p class="bl"><span class="sbl">•</span> Radiation enteritis, ischemic colitis, neoplasia (colon cancer, lymphoma)</p>
<p class="capf"><b class="calibre4">Figure 3-2</b> Workup of chronic diarrhea</p>
<p class="image"><img src="../images/00052.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="h42" class="calibre7"></a><a id="page_3-8" class="calibre7"></a><a href="part0002.html#rh48" class="calibre7">DYSMOTILITY &amp; NUTRITION</a></h2>
<p class="h2a">Functional GI disease <span class="s2">(</span><span class="s2">&lt;</span><span class="s2">30 types per Rome IV criteria;</span> <span class="s"><i class="calibre3">Gastro</i> 2016;150:1257</span><span class="s2">)</span></p>
<p class="bl"><span class="sbl">•</span> Recurrent GI sx caused by disorders of gut-brain interaction rather than structural cause</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Irritable bowel syndrome (IBS)</b> <span class="s1r">(<i class="calibre3">JAMA</i> 2015;313:949; <i class="calibre3">Gastro</i> 2015;149:1399 &amp; 2018;154:1140)</span></p>
<p class="bl1">Abd discomfort a/w ≥2 of following: improve w/ defecation, Δ stool frequency, Δ stool form</p>
<p class="bl1"><b class="calibre4">IBS-C</b> (constipation predominant) vs. <b class="calibre4">IBS-D</b> (diarrhea predominant) vs. IBS-M (mixed) vs. IBS-U (unclassified). Sx may be affected by stress, diet, lifestyle, probably microbiome.</p>
<p class="bl1"><b class="calibre4">Treatment:</b> cog. behavioral Rx, probiotics, exercise, consider gut-brain modulators (eg, TCA, SSRI), Δ diet (↓ fermentable short-chain carbohydrates)</p>
<p class="bl1">IBS-C: ↑ soluble fiber in diet, laxatives (eg, lubiprostone, linaclotide, PEG), biofeedback</p>
<p class="bl1">IBS-D: loperamide or rifaximin; eluxadoline, µ &amp; κ agonist, δ antag <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:242)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cyclic vomiting syndrome (CVS):</b> acute recurrent vomiting; a/w marijuana use, personal or FHx of migraine. Acute Rx: antiemetics, IVF, sumatriptan, BZDs; prevention: TCAs/AEDs; avoid marijuana.</p>
<p class="h2a">Gastroparesis <span class="s">(<i class="calibre3">Gastro Clinics of NA</i> 2015;44:1; <i class="calibre3">World J Gastro</i> 2015;21:6842)</span></p>
<p class="bl"><span class="sbl">•</span> Delayed gastric emptying w/o obstruction, typically p/w nausea (&gt;90%), vomiting (&gt;80%), early satiety (60%), postprandial fullness/pain</p>
<p class="bl"><span class="sbl">•</span> Etiol: DM, post-surg, post-viral, crit. illness, Parkinson’s, opiates, CCB, anti-cholin</p>
<p class="bl"><span class="sbl">•</span> Dx: gastric emptying scintigraphy</p>
<p class="bl"><span class="sbl">•</span> Treatment: prokinetic agents (metoclopramide or erythromycin), antiemetics for sx; feeding tube if refractory; intrapyloric botox &amp; gastric stimulator experimental</p>
<p class="h2a">Paralytic ileus of the colon <span class="s2">(Ogilvie’s;</span> <span class="s"><i class="calibre3">ANZ J Surg</i> 2015;85:728</span><span class="s2">) &amp; small bowel</span></p>
<p class="bl"><span class="sbl">•</span> Definition: loss of intestinal peristalsis in absence of mechanical obstruction</p>
<p class="bl"><span class="sbl">•</span> Abd discomfort &amp; distention, ↓ or absent bowel sounds, ± N/V, hiccups</p>
<p class="bl"><span class="sbl">•</span> Typically in elderly, hospitalized, ill Pts; precipitated by: intra-abd process (surgery, pancreatitis, peritonitis, intestinal ischemia), severe med illness (eg, sepsis), meds (opiates, CCB, anticholin.), metab/endo abnl (thyroid, DM, kidney failure, liver failure, hypoK), spinal cord compression/trauma, neurologic d/o (Parkinson’s, Alzheimer’s, MS)</p>
<p class="bl"><span class="sbl">•</span> KUB or CT w/ colonic dilatation (in ileus, dilated loops of SB) w/o mech obstruction; cecal diam &gt;12 cm a/w high-risk perf in Ogilvie’s</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treatment:</b> conservative measures (NPO, avoid offending meds) usually effective; IV <b class="calibre4">neostigmine</b> (monitor for bradycardia), methylnaltrexone; bowel decompression w/ NGT, rectal tube. Ogilvie’s only: colonoscopy; if refractory, colostomy or colectomy.</p>
<p class="h2a">Constipation <span class="s">(<i class="calibre3">Annals</i> 2015;162:ITC1)</span></p>
<p class="bl"><span class="sbl">•</span> Defined as dissatisfaction w/ defecation or (per Rome IV): ≥2 of following during last 3–6 mo ≥25% of the time: straining, lumpy/hard stools, incomplete evacuation, sensation of anorectal obstruction, manual maneuvers to facilitate defecation, stool frequency &lt;3/wk</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary etiologies:</b> slow transit vs. pelvic floor dyssynergia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary etiologies</b> (4 Ms)</p>
<p class="bl1">Mech obstruction: malignancy, compression, rectocele, strictures</p>
<p class="bl1">Meds: opioids, TCAs, anticholinergics, CCB, NSAIDs, diuretics, Ca<sup class="calibre15">2</sup><sup class="calibre15">+</sup>, Fe</p>
<p class="bl1">Metabolic/endo: DM, hypothyroid, uremia, preg, panhypopit, porphyria, ↑ Ca, ↓ K, ↓ Mg</p>
<p class="bl1">Myopathy/Neuro: Parkinson’s, Hirschsprung’s, amyloid, MS, spinal injury, dysautonomia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dx:</b> H&amp;P w/ DRE. Labs: consider CBC, electrolytes w/ Ca, TSH. Colonoscopy if alarm sx. Anorectal manometry/balloon expulsion test; colonic transit study; defecography.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treatment:</b> ↑ fluid &amp; fiber intake. Emollient laxative (docusate): softens stool.</p>
<p class="bl1">Bulk laxatives (psyllium, methylcellulose, polycarbophil): ↑ colonic residue, ↑ peristalsis</p>
<p class="bl1">Osmotic laxatives (Mg, NaPO<sub class="calibre8">4</sub> [avoid in CKD], lactulose, PEG): ↑ H<sub class="calibre8">2</sub>O in colon</p>
<p class="bl1">Stimulant laxatives (senna, castor oil, bisacodyl): ↑ motility &amp; secretion</p>
<p class="bl1">Enema/suppository (phosphate, mineral oil, tap water, soapsuds, bisacodyl)</p>
<p class="bl1">Lubiprostone (↑ secretion); methylnaltrexone and alvimopan for opioid-induced</p>
<p class="bl1">Plecanitide (cGMP agonist) for chronic idiopathic constipation <span class="s1r">(<i class="calibre3">Gastroenterol</i> 2016;150:S317)</span></p>
<p class="bl1">Linaclotide ↑ stool freq, ↓ straining/bloating <span class="s1r">(<i class="calibre3">Am J Gastro</i> 2018;113:105)</span></p>
<p class="h2a">Nutrition in critical illness <span class="s2">(also see “Mech Ventilation”)</span> <span class="s">(<i class="calibre3">Crit Care</i> 2015;19:35)</span></p>
<p class="bl"><span class="sbl">•</span> Enteral &amp; parenteral with similar clinical outcomes <span class="s1r">(<i class="calibre3">Lancet</i> 2018;391:133)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Enteral</b> (EN): starting w/in 48–72 hr of ICU admit may ↓ infxn &amp; mort, but repletion of 100% caloric needs may be harmful <span class="s1r">(<i class="calibre3">Cochrane</i> CD0078767)</span>. Contraindic. if obstruction, major GIB. Possible complic: ischemic bowel b/c ↑ demand for splanchnic blood; aspiration PNA.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Parenteral</b> (PN): start after 7 d if unable to tolerate enteral feeds, late (&gt; day 8 of ICU stay) Contraindic: hyperosmolality, severe electrolyte disturbances, severe hyperglycemia; sepsis is <i class="calibre3">relative</i> contraindication. Complications: hyperglycemia (due to dextrose), catheter sepsis/thrombus, refeeding syndrome, LFT abnl (steatosis, cholestasis, gallbladder sludge due to lack of enteric stimulation).</p>
<h2 class="ct"><a id="h43" class="calibre7"></a><a id="page_3-9" class="calibre7"></a><a href="part0002.html#rh49" class="calibre7">DISORDERS OF THE COLON</a></h2>
<p class="h">D<small class="calibre30">IVERTICULOSIS</small></p>
<p class="h2a">Definition &amp; pathophysiology <span class="s">(<i class="calibre3">Aliment Pharm Ther</i> 2015;42:664)</span></p>
<p class="bl"><span class="sbl">•</span> Acquired herniations of colonic mucosa &amp; submucosa in areas where vasa recta penetrate</p>
<p class="bl"><span class="sbl">•</span> Thought to occur in setting of abnormal motility and ↑ intraluminal pressure</p>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> Risk factors: ↓ fiber, ↑ red meat, obesity, smoking, physical inactivity, EtOH, NSAIDs</p>
<p class="bl"><span class="sbl">•</span> Prevalence higher w/ ↑ age (10% if &lt;40 y; 50–66% if &gt;80 y); “Westernized” societies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Left side</b> (90%, mostly sigmoid) &gt; R side of colon (except in Asia where 75–85% R-sided)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Usually asx, but 5–15% develop diverticular hemorrhage (see “GIB”) and &lt;5% diverticulitis</p>
<p class="bl"><span class="sbl">•</span> Limited data for ↑ fiber diet or avoiding nuts/seeds <span class="s1r">(<i class="calibre3">Ther Adv Gastro</i> 2016;9:213)</span></p>
<p class="h">D<small class="calibre30">IVERTICULITIS</small></p>
<p class="h2a">Pathophysiology <span class="s">(<i class="calibre3">Gastro</i> 2015;149:1944; <i class="calibre3">Am J Gastro</i> 2018;112:1868)</span></p>
<p class="bl"><span class="sbl">•</span> Retention of undigested food and bacteria in diverticulum → fecalith formation → obstruction → compromise of diverticulum’s blood supply, infection, perforation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Uncomplicated:</b> microperforation → localized infection</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Complicated</b> (15%): macroperf → abscess, peritonitis, fistula (65% w/ bladder), obstrxn</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">LLQ abdominal pain</b>, <b class="calibre4">fever</b>, nausea, vomiting, constipation or diarrhea</p>
<p class="bl"><span class="sbl">•</span> PEx ranges from LLQ tenderness ± palpable mass to peritoneal signs &amp; septic shock</p>
<p class="bl"><span class="sbl">•</span> Ddx includes IBD, infectious colitis, PID, tubal pregnancy, cystitis, colorectal cancer</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Plain abdominal radiographs to r/o free air, ileus or obstruction</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abdominal CT</b> (I<sup class="calibre15">+</sup>O<sup class="calibre15">+</sup>): &gt;95% Se &amp; Sp; assess complicated disease (abscess, fistula)</p>
<p class="bl"><span class="sbl">•</span> Colonoscopy <i class="calibre3">contraindic.</i> acutely as ↑ risk of perforation; do 6–8 wk after to r/o neoplasm</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">JAMA</i> 2017;318:291; <i class="calibre3">Dig Surg</i> 2017;34:151; <i class="calibre3">NEJM</i> 2018;379:1635)</span></p>
<p class="bl"><span class="sbl">•</span> Mild: outPt Rx indicated if Pt has few comorbidities and can tolerate POs</p>
<p class="bl1">PO abx: (MNZ + FQ) or amox/clav for 7–10 d; liquid diet until clinical improvement</p>
<p class="bl1">Possible that abx not needed for uncomplicated diverticulitis <span class="s1r">(<i class="calibre3">Br J Surg</i> 2017;104:52)</span></p>
<p class="bl"><span class="sbl">•</span> Severe: inPt Rx if cannot take POs, narcotics needed for pain, or complications</p>
<p class="bl1">NPO, IVF, NGT (if ileus); IV abx (GNR &amp; anaerobic coverage; eg, CTX/MNZ or pip-tazo)</p>
<p class="bl"><span class="sbl">•</span> Abscesses &gt;4 cm should be drained percutaneously or surgically</p>
<p class="bl"><span class="sbl">•</span> Surgery: if progression despite med Rx, undrainable abscess, free perforation</p>
<p class="bl1">Resection superior to laparoscopic lavage <span class="s1r">(<i class="calibre3">JAMA</i> 2015;314:1364)</span>, but lavage may be suitable for perforation w/ purulent peritonitis <span class="s1r">(<i class="calibre3">Annals</i> 2016;164:137)</span></p>
<p class="bl1">After source control, 4 d abx may be sufficient <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:1996)</span></p>
<p class="bl1">Resection for recurrent bouts of diverticulitis on a case-by-case basis</p>
<p class="bl1">Consider lower threshold for urgent &amp; elective surgery for immunocompromised Pts</p>
<p class="h2a">Prevention <span class="s">(<i class="calibre3">Cochrane</i> CD009839; <i class="calibre3">Am J Gastro</i> 2016;11:579; <i class="calibre3">Ann Gastro</i> 2016;29:24)</span></p>
<p class="bl"><span class="sbl">•</span> Mesalamine + rifaximin both w/ weak evidence</p>
<p class="bl"><span class="sbl">•</span> Risk of recurrence 10–30% w/in 10 y of 1<sup class="calibre15">st</sup> episode; more likely 2<sup class="calibre15">nd</sup> episode complicated</p>
<p class="h">P<small class="calibre30">OLYPS</small> &amp; A<small class="calibre30">DENOMAS</small></p>
<p class="h2a">Pathophysiology &amp; epidemiology <span class="s">(<i class="calibre3">NEJM</i> 2016;374:1065)</span></p>
<p class="bl"><span class="sbl">•</span> Accumulation of mutations in colonic epithelial cell DNA affecting oncogenes &amp; tumor suppressor genes → <i class="calibre3">tumor initiation</i> (formation of adenoma; <i class="calibre3">APC</i> loss of fxn) → <i class="calibre3">tumor progression</i> (adenoma → carcinoma; <i class="calibre3">K-ras</i> gain of fxn, <i class="calibre3">DCC, p53</i> loss of fxn)</p>
<p class="bl"><span class="sbl">•</span> Risk factors: ↑ age, FHx (sporadic in 1° relatives, Lynch, FAP), IBD, ↑ dietary fat, central adiposity, ↑ EtOH, ↓ fiber, ↑ red meat, ? smoking, DM</p>
<p class="bl"><span class="sbl">•</span> Protective factors: ↑ physical activity, ASA/NSAIDs, Ca<sup class="calibre15">2</sup><sup class="calibre15">+</sup> intake, HRT, ↓ BMI; possibly ↑ fiber, vitamin D, fish oil, statins, selenium</p>
<p class="bl"><span class="sbl">•</span> Neoplastic polyps: adenomas (tubular, villous, tubulovillous dysplasia), sessile serrated adenomas/polyps (concern for interval CRC), carcinomas</p>
<p class="bl"><span class="sbl">•</span> Nonneoplastic polyps: hyperplastic, juvenile, Peutz-Jeghers, inflammatory</p>
<p class="h2a">Detection</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Colonoscopy</i> is gold standard</p>
<p class="bl"><span class="sbl">•</span> Recommended in all Pts starting at age 50 (Amer Cancer Soc. rec age 45) and then typically q10y unless pathology found</p>
<p class="bl"><span class="sbl">•</span> If ⊕ FHx, start age 40, or 10 y before age of dx in youngest family member, repeat q5y</p>
<h2 class="ct"><a id="h44" class="calibre7"></a><a id="page_3-10" class="calibre7"></a><a href="part0002.html#rh50" class="calibre7">INFLAMMATORY BOWEL DISEASE</a></h2>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ulcerative colitis (UC):</b> inflammation of the colonic <i class="calibre3">mucosa; contiguous</i>, starting at rectum</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Crohn’s disease (CD):</b> <i class="calibre3">transmural</i> inflammation anywhere along GI tract, <i class="calibre3">skip lesions</i></p>
<p class="h2a">Epidem &amp; pathophys <span class="s">(<i class="calibre3">Lancet</i> 2016;387:156 &amp; 2017;390:2769)</span></p>
<p class="bl"><span class="sbl">•</span> Prevalence ~1-3:1000 in N Am; ↑ incidence in Caucasians, Jews, newly industrialized</p>
<p class="bl"><span class="sbl">•</span> Age of onset 15–30 y; ? bimodal w/ 2<sup class="calibre15">nd</sup> peak at 50–70 y; 1:1 M:F in N America</p>
<p class="bl"><span class="sbl">•</span> Smokers at ↑ risk for CD, whereas nonsmokers &amp; former smokers at ↑ risk for UC</p>
<p class="bl"><span class="sbl">•</span> Genetic predisposition + environmental risk factors → T cell dysregulation → inflammation</p>
<p class="h">U<small class="calibre30">LCERATIVE</small> C<small class="calibre30">OLITIS</small> <span class="s1">(<i class="calibre22">Lancet</i> 2018;389:1756)</span></p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Grossly bloody diarrhea</b>, lower abdominal cramps, urgency, tenesmus</p>
<p class="bl"><span class="sbl">•</span> Extracolonic (&gt;25%): erythema nodosum, pyoderma gangrenosum, aphthous ulcers, uveitis, episcleritis, thromboembolic events (esp. during a flare; <i class="calibre3">Lancet</i> 2010;375:657), AIHA, seroneg arthritis, chronic hepatitis, cirrhosis, PSC (↑ risk cholangio CA, CRC)</p>
<p class="bl"><span class="sbl">•</span> Multiple scores for assessing dis. severity clinically: Truelove &amp; Witts; SCCAI</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Colonoscopy:</b> involves rectum (95%) &amp; extends prox., usu circumfer., &amp; <i class="calibre3">contig. w/in colon</i></p>
<p class="bl"><span class="sbl">•</span> Location: proctitis (30–60%), L-sided (15–45%) and extensive (pancolitis; 15–35%)</p>
<p class="bl"><span class="sbl">•</span> Appearance: vascularity loss, friable mucosa, diffuse ulceration, <i class="calibre3">pseudopolyps</i> (chronicity)</p>
<p class="bl"><span class="sbl">•</span> Histology: superficial chronic inflammation; crypt abscesses &amp; architectural distortion</p>
<p class="bl"><span class="sbl">•</span> Barium enema with featureless and tubular appearance of colon (<i class="calibre3">leadpipe appearance</i>)</p>
<p class="bl"><span class="sbl">•</span> Flares: ↑ ESR &amp; CRP (not Se or Sp); ⊕ fecal calprotectin helpful in distinguishing IBD vs. IBS and monitoring for IBD flare <span class="s1r">(<i class="calibre3">Gastro Hep</i> 2017;13:53)</span></p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Toxic megacolon</b> (5%): colon dilatation (≥6 cm on KUB), colonic atony, systemic toxicity, &amp; ↑ risk of perf. Rx w/ IV steroids &amp; broad-spectrum abx; surgery if needed.</p>
<p class="bl"><span class="sbl">•</span> Stricture (rectosigmoid), dysmotility, anorectal dysfxn after recurrent inflammation</p>
<p class="bl"><span class="sbl">•</span> CRC and dysplasia (<i class="calibre3">see below</i>)</p>
<p class="bl"><span class="sbl">•</span> For Pts s/p surgery w/ ileal pouch, may develop <i class="calibre3">pouchitis</i> (inflammation of ileal pouch, up to ½ of pts). Rx w/ abx (MNZ, cipro), probiotics.</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> 50% in remission at any given time. Intermittent exacerbations in 90%; continual active disease in ~18%. Prox progression in 25% at 10 y. Rate of colectomy at 10 y is 24%.</p>
<p class="bl"><span class="sbl">•</span> Mortality rate of severe UC flare is &lt;2%, &amp; overall life expectancy in UC = non-UC Pts</p>
<p class="h">C<small class="calibre30">ROHN’S</small> D<small class="calibre30">ISEASE</small> <span class="s1">(<i class="calibre22">Lancet</i> 2018;389:1741)</span></p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Nat Rev Gastro Hep</i> 2016;13:567)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abdominal pain</b>, loose/frequent stools (up to 50% ⊕ FOBT), fever, malaise, wt loss</p>
<p class="bl"><span class="sbl">•</span> Mucus-containing, <b class="calibre4">nongrossly bloody diarrhea</b></p>
<p class="bl"><span class="sbl">•</span> N/V, bloating, obstipation if presence of obstruction; extracolonic manifestations as in UC</p>
<p class="bl"><span class="sbl">•</span> Multiple scoring systems: CD Activity Index (CDAI), Harvey-Bradshaw Index</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ileocolonoscopy + bx</b> along w/ <b class="calibre4">small bowel assessment</b> (eg, MR-enterography)</p>
<p class="bl"><span class="sbl">•</span> Small bowel/ileitis (~25%), ileocolonic (~50%), colonic (~25%); isolated upper tract rare</p>
<p class="bl"><span class="sbl">•</span> Appearance: nonfriable mucosa, cobblestoning, aphthous ulcers, deep &amp; long <b class="calibre4">fissures</b></p>
<p class="bl"><span class="sbl">•</span> Histology: <b class="calibre4">transmural inflammation</b> with mononuclear cell infiltrate, <b class="calibre4">noncaseating granulomas</b> (seen in &lt;25% of mucosal biopsies), fibrosis, ulcers, fissures</p>
<p class="bl"><span class="sbl">•</span> Montreal classification: age at dx, disease location &amp; behavior (stricturing vs. nonstricturing, penetrating vs. nonpenetrating), plus modifiers for upper tract &amp; perianal disease</p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Perianal disease:</b> fissures, fistulas, skin tags, perirectal abscesses (in 24% of Pts; perianal disease <i class="calibre3">precedes</i> intestinal symptomatology)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stricture:</b> small bowel, postprandial abd pain; can lead to complete SBO &amp; require surgery</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fistulas:</b> perianal, enteroenteric, rectovaginal, enterovesicular, enterocutaneous</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abscess:</b> fever, tender abd mass, ↑ WBC; <i class="calibre3">steroids mask sx</i>, ∴ need high-level suspicion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Malabsorption:</b> ileal disease/resection: ↓ bile acids abs → gallstones; ↓ fatty acid abs → Ca oxalate kidney stones; ↓ fat-soluble vitamin abs → vit D deficiency → <i class="calibre3">osteopenia</i></p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> Variable at 1 y: ~50% in remission, ~20% flare, ~20% low activity, ~10% chronic active</p>
<p class="bl"><span class="sbl">•</span> At 20 y, majority will have required some surgery; overall life expectancy is slightly ↓</p>
<p class="h"><a id="page_3-11" class="calibre7"></a>M<small class="calibre30">ANAGEMENT</small> <span class="s1">(<i class="calibre22">Lancet</i> 2016;398:1756; <i class="calibre22">Mayo Clin Proc</i> 2017;92:1088)</span></p>
<p class="h2a">Initial evaluation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">H&amp;P</b> (✔ for intestinal &amp; extraintestinal manifestations) and <b class="calibre4">dx studies</b> as above</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lab:</b> consider CBC/diff, LFTs, iron studies, B12, folate, vit D, ESR, CRP, fecal calprotectin</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Exclude other etiologies:</b> infectious (espec. TB), ischemic colitis, intestinal lymphoma, CRC, IBS, vasculitis, Behçet’s, celiac disease, small intestinal bacterial overgrowth</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">R/o infection</b> (esp. TB, HBV, CMV) before treating with immunosuppressants and biologics (although not all acutely hospitalized Pts w/ IBD need infxn r/o prior to Rx)</p>
<p class="h2a">Goals of treatment <span class="s">(<i class="calibre3">Ther Adv Gastro</i> 2015;8:143)</span></p>
<p class="bl"><span class="sbl">•</span> Induce remission of acute flare → maintain remission; mucosal healing 1° goal</p>
<p class="bl"><span class="sbl">•</span> Step up Rx (least → most toxic) typical approach; consider early biologic if severe disease</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Medical Therapy for IBD</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tabheadc"><b class="calibre4"><i class="calibre3">Ulcerative Colitis</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mild</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">5-ASA:</b> many formulations (sulfasalazine, mesalamine, olsalazine, balsalazide) depending on disease location. Used for induction &amp; maintenance of remission. Complications: diarrhea, abd pain, pancreatitis.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mild- moderate</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">MMX-budesonide:</b> PO budesonide released throughout colon for flare. 1<sup class="calibre35">st</sup>-pass metab ↓ systemic adverse effects of steroid.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Moderate-severe</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">PO prednisone:</b> 40–60 mg w/ taper over several wks to induce remission</p>
<p class="tabh"><b class="calibre4">AZA/6-MP:</b> 0.5–1 mg/kg and uptitrate over several wks for maintenance; ↑ remission rate when AZA combined w/ IFX (<span class="tfont"><i class="calibre3">Gastro</i> 2014;146:392)</span>. Complic: BM suppression, lymphoma, pancreatitis, hepatitis; ✔ TPMT levels prior to dosing to ↓ risk of generation of toxic metabs. In selected cases, add allopurinol to boost activity in non-responders.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Severe or refractory disease</b></p>
<p class="tab">(<span class="tfont"><i class="calibre3">Lancet</i> 2014; 384:309 &amp; 2017;389:1218; <span class="calibre19"><i class="calibre3">NEJM</i></span> 2016; 374:1754 &amp; 2017; 76:1723; <span class="calibre19"><i class="calibre3">JAMA</i></span> 2019; 321:156)</span></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">IV steroids:</b> eg, 100 mg hydrocort q8h or 16–20 mg methylpred q8h to induce remission w/ plan to taper &amp; switch to non-steroid maintenance.</p>
<p class="tabh"><b class="calibre4">Cyclosporine:</b> for severe flares refractory to steroids, 2–4 mg/kg infusion × 7 d w/ goal to Δ to maintenance medication (eg, AZA/6-MP)</p>
<p class="tabh"><b class="calibre4">Anti-TNF</b> (infliximab, adalimumab &amp; golimumab): for steroid-refractory flares or to maintain remission. Complic: reactiv. TB (✔ PPD prior to Rx) or viral hepatitis; small ↑ risk NHL; lupus-like rxn, psoriasis, MS, CHF.</p>
<p class="tabh"><i class="calibre3">For TNF refractory, alternative biologic for induction &amp; maintenance:</i> <b class="calibre4">vedolizumab</b> (α4β7 integrin inhibitor); <b class="calibre4">tofacitinib</b> (JAK inh)</p>
<p class="tabh"><i class="calibre3">Investigational:</i> fecal microbiota transplant (mixed data – efficacy may depend on mode of delivery &amp; prep); etrolizumab (α4β7 inhib); ozanimod (sphinosine-1-phosphate receptor agonist)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tabheadc"><b class="calibre4"><i class="calibre3">Crohn’s Disease</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mild</b></p></td>
<td class="bg0-b"><p class="tab">Consider <b class="calibre4">5-ASA</b> for colonic Crohn’s disease</p>
<p class="tab"><b class="calibre4">Abx:</b> FQ/MNZ or amo x/clav for pyogenic complic (fistulas, perineal dis.)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mild-mod</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Budesonide:</b> PO, but pH ± time-dep release → ileum &amp; ascending colon</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Moderate-severe</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">PO prednisone:</b> same as UC, for inducing remission, not maintenance</p>
<p class="tab"><b class="calibre4">AZA/6-MP:</b> same as UC; ↑ remission w/ AZA+IFX (<span class="tfont"><i class="calibre3">NEJM</i> 2010; 362:1383)</span></p>
<p class="tab"><b class="calibre4">MTX:</b> 15–25 mg IM/SC or PO qwk for maintenance; 1–2 mo to take effect</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Severe or refractory disease</b> (<span class="tfont"><i class="calibre3">NEJM</i> 2016; 375:1946)</span></p></td>
<td class="bg"><p class="tab"><b class="calibre4">Anti-TNF:</b> infliximab, adalimumab or certolizumab (pegylated)</p>
<p class="tabh">If flare on infliximab, ✔ trough &amp; presence of anti-inflixi Ab. Low &amp; ⊖ Ab → ↑ dose/freq. If ⊕ Ab → Δ to other biologic (<span class="tfont"><i class="calibre3">Am J Gastro</i> 2011;106:685)</span>.</p>
<p class="tab"><b class="calibre4">Vedolizumab</b> (anti-α4β7 integrin); <b class="calibre4">ustekinumab</b> (anti-IL 12/23)</p>
<p class="tabh"><i class="calibre3">Investigational:</i> tofacitinib and filgotinib (JAK-inh; <span class="tfont"><i class="calibre3">Lancet</i> 2017;389:266</span>); adipose- derived stem cells <span class="tfont">(<i class="calibre3">Lancet</i> 2016; 388:1281)</span></p></td>
</tr>
</table>
<p class="h2a">Surgery</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">UC:</b> colectomy if sx refractory to or intolerable side effects from meds, CRC, perforation, toxic megacolon, uncontrolled hemorrhage. Often <i class="calibre3">ileal pouch-anal anastomosis</i> (IPAA).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CD:</b> resection if refractory disease; endoscopic dilation or surgery for strictures; diverting ileostomy for perineal disease</p>
<p class="h2a">Cancer screening <span class="s">(<i class="calibre3">NEJM</i> 2015;372:1441)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Colon cancer:</b> risk in UC ~2% at 10 y, ~8% at 20 y, ~18% at 30 y. Similar for colonic CD, plus risk of small bowel cancer as well. Dysplasia best marker for risk. Other risk factors include: PSC, ⊕ FHx, greater extent of disease, stricture, &amp; pseudopolyps.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Surveillance:</b> <i class="calibre3">colonoscopy</i> w/ random bx 8 y after dx to eval for dysplasia, q1–3y thereafter based on risk factors. <i class="calibre3">Chromoendoscopy</i> using dye to stain high-risk lesions for targeted bx is emerging technique. If high-grade dysplasia or dysplasia-assoc. lesion/mass → colectomy.</p>
<h2 class="ct"><a id="h45" class="calibre7"></a><a id="page_3-12" class="calibre7"></a><a href="part0002.html#rh51" class="calibre7">INTESTINAL ISCHEMIA</a></h2>
<p class="h">A<small class="calibre30">CUTE</small> M<small class="calibre30">ESENTERIC</small> I<small class="calibre30">SCHEMIA</small></p>
<p class="h2a">Definition and causes <span class="s">(<i class="calibre3">NEJM</i> 2016;374:959)</span></p>
<p class="bl"><span class="sbl">•</span> Reduced or absent blood flow to small intestine, typically caused by <i class="calibre3">arterial</i> (ie, SMA or its branches) occlusion or transient hypoperfusion or less often by <i class="calibre3">venous</i> occlusion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arterial embolism</b> (~40–50%): embolic occlusion to SMA (has narrow take-off angle), often in setting of AF, valvular disease incl. endocarditis, atherosclerotic plaque in aorta</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">SMA thrombosis</b> (~20–30%): typically due to atherosclerosis at origin of SMA; other risk factors incl. vascular injury from abd trauma, infxn, or mesenteric dissections/aneurysms</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonocclusive mesenteric ischemia</b> (~10%): transient intestinal hypoperfusion due to ↓ CO, athero, sepsis, drugs that ↓ gut perfusion (pressors, cocaine, amphetamines)</p>
<p class="bl"><span class="sbl">•</span> Mesenteric <b class="calibre4">venous thrombosis</b> (MVT, ~5%): a/w hypercoag. states, portal hypertension, IBD, malignancy, inflammation (pancreatitis, peritonitis), pregnancy, trauma, surgery</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Focal segmental ischemia of small bowel</b> (&lt;5%): vascular occlusion to small segments of small bowel (vasculitis, atheromatous emboli, strangulated hernias, XRT)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Total arterial or venous occlusion: <b class="calibre4">sudden abd pain out of proportion to abdominal tenderness on exam</b>, progressing to frank infarction w/ peritoneal signs if untreated</p>
<p class="bl"><span class="sbl">•</span> Nonocclusive: abd distention &amp; pain, n/v, <b class="calibre4">lower GI bleeding</b> due to mucosal sloughing; often occurring after episode of hypoperfusion (eg, cardiac event or shock)</p>
<p class="bl"><span class="sbl">•</span> Exam ranges: unremarkable ± abd distention to peritoneal (infarction); ⊕ <b class="calibre4">FOBT ~75%</b></p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Dx relies on high level of suspicion; rapid dx essential to avoid infarction (occurs w/in hrs)</p>
<p class="bl"><span class="sbl">•</span> Mortality 20 to &gt;70% if bowel infarcted; dx prior to infarction strongest predictor of survival</p>
<p class="bl"><span class="sbl">•</span> Laboratory: often nl; ~75% ↑ WBC; ↑ amylase, LDH, PO<sub class="calibre8">4</sub>, D-dimer; ~50% ↑ lactate (late)</p>
<p class="bl"><span class="sbl">•</span> KUB: nl early before infarct; “thumbprinting,” ileus, pneumatosis in later stages</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CT angiography</b> (arterial phase): noninvasive test of choice; <i class="calibre3">venous</i> phase for dx MVT</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Angiography:</b> gold standard; potentially therapeutic; indicated if vasc occlusion suspected</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2016;374:959; <i class="calibre3">World J Emerg Surg</i> 2017;12:38)</span></p>
<p class="bl"><span class="sbl">•</span> IVF, NPO, <b class="calibre4">optimize hemodynamics</b> (minimize pressors), <b class="calibre4">broad-spectrum abx</b>, <b class="calibre4">anti-coagulation</b> w/ heparin ± <b class="calibre4">tPA</b> (for occlusive disease), <b class="calibre4">IV papaverine</b> (vasodilator; for non-occlusive mesenteric ischemia)</p>
<p class="bl"><span class="sbl">•</span> If evidence of peritonitis: to OR for surgical endovascular therapies &amp; bowel resection</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">SMA thrombosis:</b> percutaneous (stenting) or surgical revascularization</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">SMA embolism:</b> embolectomy (catheter-based aspiration vs. surgical)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonocclusive:</b> correct underlying cause (esp. cardiac)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mesenteric venous thrombosis:</b> 3–6 mo warfarin after initial heparinization. Fibrinolysis or thrombectomy typically reserved for Pts w/ hemodynamic instability or refractory sx.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Focal segmental ischemia:</b> typically surgical resection</p>
<p class="h">C<small class="calibre30">HRONIC</small> M<small class="calibre30">ESENTERIC</small> I<small class="calibre30">SCHEMIA</small></p>
<p class="bl"><span class="sbl">•</span> Definition and causes: ↓ blood flow to gut typically because of mesenteric atherosclerosis</p>
<p class="bl"><span class="sbl">•</span> Sx: “intestinal angina” = <b class="calibre4">postprandial abd pain</b>, early satiety, &amp; ↓ wt due to fear of eating. If pain becomes constant → could represent acute thrombosis (see above).</p>
<p class="bl"><span class="sbl">•</span> Dx: duplex U/S or CTA; angiography gold std; gastric tonometry exercise testing</p>
<p class="bl"><span class="sbl">•</span> Treatment: surgical revascularization (1<sup class="calibre15">st</sup> line); could also consider angioplasty ± stenting</p>
<p class="h">I<small class="calibre30">SCHEMIC</small> C<small class="calibre30">OLITIS</small></p>
<p class="h2a">Definition &amp; pathophysiology</p>
<p class="bl"><span class="sbl">•</span> Nonocclusive disease 2° to Δs in systemic circulation or anatomic/fxnal Δs in local mesenteric vasculature; often underlying etiology unknown, frequently seen in elderly</p>
<p class="bl"><span class="sbl">•</span> “Watershed” areas (splenic flexure &amp; rectosigmoid) most susceptible; 25% involve R side; confers worse prognosis <span class="s1r">(<i class="calibre3">Clin Gastroenterol Hepatol</i> 2015;13:1969)</span></p>
<p class="h2a">Clinical manifestations, diagnosis, &amp; treatment</p>
<p class="bl"><span class="sbl">•</span> Usually p/w <b class="calibre4">cramping LLQ pain w/ overtly bloody stool;</b> fever and peritoneal signs should raise clinical suspicion for infarction</p>
<p class="bl"><span class="sbl">•</span> Disease spectrum: reversible colopathy (35%), transient colitis (15%), chronic ulcerating colitis (20%), resulting stricture (10%), gangrene (15%), fulminant colitis (&lt;5%)</p>
<p class="bl"><span class="sbl">•</span> Dx: <b class="calibre4">flex sig/colonoscopy</b> or <b class="calibre4">CT abd/pelvis</b> to make diagnosis; r/o IBD, infectious colitis</p>
<p class="bl"><span class="sbl">•</span> Treatment: bowel rest, IV fluids, <b class="calibre4">broad-spectrum abx</b>, serial abd exams; <b class="calibre4">surgery</b> for infarction, fulminant colitis, hemorrhage, failure of med Rx, recurrent sepsis, stricture</p>
<p class="bl"><span class="sbl">•</span> Resolution w/in 48 h w/ conservative measures occurs in &gt;50% of cases</p>
<h2 class="ct"><a id="h46" class="calibre7"></a><a id="page_3-13" class="calibre7"></a><a href="part0002.html#rh52" class="calibre7">PANCREATITIS</a></h2>
<p class="h">A<small class="calibre30">CUTE</small> P<small class="calibre30">ANCREATITIS</small></p>
<p class="h2a">Pathogenesis</p>
<p class="bl"><span class="sbl">•</span> Pancreatic duct and acinar injury via direct or indirect toxicity → impaired secretion and premature activation of digestive enzymes → autodigestion and acute inflammation</p>
<p class="h2a">Etiologies <span class="s">(<i class="calibre3">NEJM</i> 2016;375:1972)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Gallstones</b> (40%): ♀ &gt; ♂; usually due to small stones (&lt;5 mm) or microlithiasis/sludge</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Alcohol</b> (30%): ♂ &gt; ♀; 4–5 drinks/day over ≥5 yrs; usually chronic w/ acute flares</p>
<p class="bl"><span class="sbl">•</span> Metabolic: hypertrig. (2–5%; TG &gt;1000; type I &amp; V familial hyperlipemia); hyperCa</p>
<p class="bl"><span class="sbl">•</span> Drugs (&lt;5%): 5-ASA, 6-MP/AZA, ACEI, cytosine, didanosine, dapsone, estrogen, furosemide, isoniazid, MNZ, pentamidine, statins, sulfa, thiazides, tetracycline, valproate</p>
<p class="bl"><span class="sbl">•</span> Anatomic: divisum, annular pancreas, duodenal duplication cysts, Sphincter of Oddi dysfxn</p>
<p class="bl"><span class="sbl">•</span> Autoimmune (qv)</p>
<p class="bl"><span class="sbl">•</span> Familial: suspect if early onset (age &lt;20 y); cause acute and chronic pancreatitis (qv)</p>
<p class="bl"><span class="sbl">•</span> Infections: ascaris, clonorchis, coxsackie, CMV, EBV, HIV, mumps, mycoplasma, TB, toxo</p>
<p class="bl"><span class="sbl">•</span> Ischemia: shock, vasculitis, cholesterol emboli</p>
<p class="bl"><span class="sbl">•</span> Neoplastic: panc/ampullary tumors, mets (RCC most common, breast, lung, melanoma)</p>
<p class="bl"><span class="sbl">•</span> Post ERCP (5%): Ppx w/ PR indomethacin can ↓ sx; temporary panc duct stent if high risk</p>
<p class="bl"><span class="sbl">•</span> Trauma: blunt abdominal trauma, post-pancreatic/biliary surgery</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Epigastric abdominal or LUQ pain (90%)</b>, only ½ w/ bandlike pain radiating to back</p>
<p class="bl"><span class="sbl">•</span> 10% pain-free (due to analgesic/steroid use, immunosuppressed, ΔMS, ICU, post-op), ∴ ✔ amylase/lipase in unexplained shock</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">N/V (90%),</b> abd tenderness/guarding, ↓ bowel sounds, jaundice if biliary obstruction</p>
<p class="bl"><span class="sbl">•</span> Ddx: acute cholecystitis, perforated viscus, SBO, mesenteric ischemia, IMI, AAA leak, distal aortic dissection, ruptured ectopic pregnancy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Early phase</b> (&lt;1 wk): possible SIRS ± organ failure; <b class="calibre4">late</b> (&gt;1 wk): local complications (qv)</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">Am J Gastro</i> 2013;108:1400)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dx requires 2 of 3:</b> characteristic abd pain; lipase or amylase &gt;3× ULN; ⊕ imaging</p>
<p class="bl"><span class="sbl">•</span> Laboratory: levels of amylase &amp; lipase do <i class="calibre3">not</i> correlate w/ severity of disease</p>
<p class="bl1">↑ <b class="calibre4">amylase</b>: rises w/in hrs, normalizes w/in 3–5 d (faster than lipase)</p>
<p class="bl2">false ⊖: 20% EtOH pancreatitis; 50% hypertriglyceridemia (assay interference)</p>
<p class="bl2">false ⊕: other abd or salivary gland process, acidemia, ↓ GFR, macroamylasemia</p>
<p class="bl1">↑ <b class="calibre4">lipase</b>: longer t<sub class="calibre8">½</sub> than amylase</p>
<p class="bl2">&gt;3× ULN 99% sensitive, 99% specific for acute pancreatitis</p>
<p class="bl2">&gt;10k has 80% PPV for biliary dx, 99% NPV for EtOH <span class="s1r">(<i class="calibre3">Dig Dis Sci</i> 2011;56:3376)</span></p>
<p class="bl2">false ⊕: renal failure, other abd process, DKA, HIV, macrolipasemia</p>
<p class="bl1">ALT &gt;3× ULN has 95% PPV for gallstone pancreatitis <span class="s1r">(<i class="calibre3">Am J Gastro</i> 1994;89:1863)</span></p>
<p class="bl"><span class="sbl">•</span> Imaging studies <span class="s1r">(<i class="calibre3">Am J Gastro</i> 2013;108:1400)</span></p>
<p class="bl1"><b class="calibre4">Abd U/S:</b> typically not useful to visualize pancreas (obscured by bowel gas), but <i class="calibre3">should be ordered for all Pts to r/o biliary etiology</i> (ie, gallstones, BD dilatation)</p>
<p class="bl1"><b class="calibre4">Abd CT:</b> not rec for initial eval unless dx unclear (local complic. not yet visible &amp; concern for AKI w/ IV contrast). However, if persistent pain and/or clinical deterioration after 48–72 h, CT(I<sup class="calibre15">+</sup>) useful to r/o local complications (necrosis, fluid collections).</p>
<p class="bl1">MRI/MRCP: Can detect necrosis; also used to assess for stones &amp; ductal disruption</p>
<p class="bl1">Endoscopic U/S (EUS): useful for occult biliary disease (microlithiasis)</p>
<p class="h2a">Severity <span class="s">(<i class="calibre3">Gut</i> 2013;62:102)</span></p>
<p class="bl"><span class="sbl">•</span> Severity defined by presence of organ failure (AKI, resp failure, GIB, shock) &amp; local or systemic complic. (panc necrosis, fluid collections, gastric outlet obstrxn, splenic &amp; PVT).</p>
<p class="bl1"><b class="calibre4">Mild:</b> 80% of cases; no organ failure or local/systemic complications; low mortality</p>
<p class="bl1"><b class="calibre4">Moderate:</b> transient (&lt;48 h) organ failure ± local/systemic complications, high morbidity</p>
<p class="bl1"><b class="calibre4">Severe:</b> persistent (&gt;48 h) organ failure, very high mortality</p>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">NEJM</i> 2016;375:1972)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ranson’s, APACHE II:</b> predict severity at 48 h using multiple physiolog. criteria; poor PPV</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">BISAP:</b> simple 5-point scoring system (BUN &gt;25, impaired MS, SIRS, age &gt;60 y, pleural effusion) used w/in first 24 h; score ≥3 predicts ↑ risk of organ failure, mortality</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CTSI:</b> CT data at 48–72h (fluid collect., necrosis) to predict mortality; can lag behind clinical</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2016;375:1972; <i class="calibre3">Am J Gastro</i> 2017;112:797)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fluid resuscitation:</b> <i class="calibre3">aggressive in 1</i><sup class="calibre15"><i class="calibre22">st</i></sup> <i class="calibre3">24 hrs, even if mild.</i> 20 ml/kg IVB → 3 ml/kg/hr. Goal to ↓ BUN &amp; Hct over 12–24 h. ✔ UOP. LR may be superior to NS (↓ SIRS; avoid if ↑ Ca).</p>
<p class="bl"><a id="page_3-14" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Nutrition</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2014;317:1983)</span></p>
<p class="bl1">Early enteral feeding encouraged, though not superior to oral feeding at 72 h</p>
<p class="bl1">Mild: Start feeding once without N/V or ileus; may not need to be completely pain free. Low-fat low-residue diet as safe as liquid diet and a/w shorter LOS.</p>
<p class="bl1">Severe: early (w/in 48–72 h) enteral nutrition indicated and preferred over TPN b/c ↓ infectious complications, organ failure, surgical interventions, and mortality.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Analgesia:</b> IV opioids (monitor respiratory status, adjust dosing if ↑ renal impairment)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Gallstone pancreatitis:</b> urgent (w/in 24 h) ERCP w/ sphincterotomy if cholangitis, sepsis, or Tbili ≥5. If mild, CCY during initial hosp to ↓ risk of recurrence <span class="s1r">(<i class="calibre3">Lancet</i> 2015;386:1261)</span>; defer surgery if necrotizing panc. until improvement in inflam. &amp; fluid collections.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypertriglyceridemia:</b> insulin gtt (activates lipoprotein lipase), fibrates, ± apheresis</p>
<p class="bl"><span class="sbl">•</span> No role for ppx abx in absence of infectious complications <span class="s1r">(<i class="calibre3">World J Gastro</i> 2012;18:279)</span></p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Systemic: ARDS, abdominal compartment syndrome, AKI, GIB (pseudoaneurysm), DIC</p>
<p class="bl"><span class="sbl">•</span> Metabolic: hypocalcemia, hyperglycemia, hypertriglyceridemia</p>
<p class="bl"><span class="sbl">•</span> Fluid collections:</p>
<p class="bl1"><b class="calibre4">Acute fluid collection:</b> seen early, not encapsulated, most resolve w/in 1–2 wk w/o Rx</p>
<p class="bl1"><b class="calibre4">Pseudocyst:</b> ~4 wk after initial attack, encapsulated. No need for Rx if asx (regardless of size/location). If sx → endoscopic <span class="s1r">(<i class="calibre3">Gastro</i> 2013;145:583)</span> vs. perc/surg drainage.</p>
<p class="bl"><span class="sbl">•</span> Pancreatic necrosis: Nonviable pancreatic tissue. CT-guided FNA if infection suspected.</p>
<p class="bl1"><b class="calibre4">Sterile necrosis:</b> if asx, can be managed expectantly, no role for ppx abx</p>
<p class="bl1"><b class="calibre4">Infected necrosis</b> (5% of all cases, 30% of severe): high mortality. Rx w/ carbapenem or MNZ+FQ. If stable, defer drainage to &gt;4 wk to allow liquefication and WOPN (qv). If sx or unstable, perc drainage &amp; minimally invasive surg debridement or endoscopic necrosectomy superior to open necrosectomy <span class="s1r">(<i class="calibre3">NEJM</i> 2010;362:1491)</span>.</p>
<p class="bl1"><b class="calibre4">WOPN</b> (walled off panc. nec.): fibrous wall surrounds necrosis over ≥4 wk; endoscopic or perc. drainage (preferred over open necrosectomy) if infected or symptomatic</p>
<p class="h">C<small class="calibre30">HRONIC</small> P<small class="calibre30">ANCREATITIS</small></p>
<p class="h2a">Pathogenesis &amp; etiology <span class="s">(<i class="calibre3">Gastro</i> 2013;144:1292; <i class="calibre3">BMJ</i> 2018;361:k2126)</span></p>
<p class="bl"><span class="sbl">•</span> Often recurrent acute attacks → inflam infiltrate → fibrosis → loss of exocrine &amp; endocrine tissue. Pancreatic insufficiency (DM, fat/protein malabsorption) when 90% panc fxn lost.</p>
<p class="bl"><span class="sbl">•</span> TIGAR-O: <b class="calibre4">T</b>oxins (60–80% due to EtOH; smoking), <b class="calibre4">I</b>diopathic, <b class="calibre4">G</b>enetic (PRSS1, SPINK1, CFTR, CTRC, CASR), <b class="calibre4">A</b>utoimmune, <b class="calibre4">R</b>ecurrent panc., <b class="calibre4">O</b>bstruction</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Epigastric pain, N/V; over time can be painless; signs of exocrine insuff (steatorrhea, wt loss) or endocrine insuff (DM: polydipsia, polyuria)</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">Pancreas</i> 2014;43:1143)</span></p>
<p class="bl"><span class="sbl">•</span> Labs: amylase/lipase ↑ early, may be nl later. ⊕ fecal fat, ↓ stool elastase &amp; A1AT. Mixed TG breath test alternative to stool elastase. ✔ A1c, consider IgG4/ANA &amp; genetic testing if young or ⊕ FHx. If dx w/ CP, measure baseline fat-soluble vitamins (ADEK).</p>
<p class="bl"><span class="sbl">•</span> Imaging: Ca<sup class="calibre15">2</sup><sup class="calibre15">+</sup> on KUB/CT. ERCP/MRCP/EUS: high sens for dx; may show stricture, dilated ducts. IV secretin stim w/ MRI may ↑ dx yield. Panc fxn test not widely available.</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Gastro</i> 2011;141:536; <i class="calibre3">Lancet</i> 2016;387:1957)</span></p>
<p class="bl"><span class="sbl">•</span> Pancreatic enzyme replacement (may ↓ pain by reducing CCK). Rx routine vitamin D &amp; Ca.</p>
<p class="bl"><span class="sbl">•</span> Pain control: smoking &amp; EtOH cessation, analgesics, pregabalin, endoscopy (stone removal or stenting strictures), celiac nerve plexus block, surgery</p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Pseudocysts, pseudoaneurysms, pancreatic ascites or pleural eff., 13× ↑ <b class="calibre4">risk of panc Ca</b></p>
<p class="h">A<small class="calibre30">UTOIMMUNE</small> P<small class="calibre30">ANCREATITIS</small></p>
<p class="h2a">Pathogenesis <span class="s">(<i class="calibre3">Am J Gastro</i> 2018;113:1301)</span></p>
<p class="bl"><span class="sbl">•</span> Type 1: lymphoplasmacytic sclerosing panc. w/ dense fibrosis; ↑ IgG4; high relapse</p>
<p class="bl"><span class="sbl">•</span> Type 2: idiopathic duct-centric pancreatitis; minimal IgG4; a/w IBD; fewer relapses</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abdominal pain</b>, can p/w obstructive jaundice and panc mass mimicking panc Ca</p>
<p class="bl"><span class="sbl">•</span> Can be primary, or in a/w IgG4 cholangitis, salivary gland disease (eg, Sjögren’s), mediastinal or RP fibrosis, interstitial nephritis, autoimmune thyroiditis, UC/PSC, RA</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Labs: cholestatic LFTs (↑ Aφ &gt; AST/ALT), ↑ γ-globulins and IgG4, ⊕ ANA, RF</p>
<p class="bl"><span class="sbl">•</span> HISORt criteria: Histology, Imaging (“sausage pancreas”, bile duct stricture), Serology, other Organ involvement, Response to therapy</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Corticosteroids 1<sup class="calibre15">st</sup>-line; immunomod. (AZA, MMF, cyclophosphamide, rituximab) if relapse</p>
<h2 class="ct"><a id="h47" class="calibre7"></a><a id="page_3-15" class="calibre7"></a><a href="part0002.html#rh53" class="calibre7">ABNORMAL LIVER TESTS</a></h2>
<p class="h2a">Tests of hepatocellular injury or cholestasis <span class="s">(<i class="calibre3">J Clin Transl Hepatol</i> 2017;5:394)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aminotransferases</b> (AST, ALT): intracellular enzymes released 2° necrosis/inflammation</p>
<p class="bl1">ALT more specific for liver than is AST (heart, skeletal muscle, kidney, brain, RBC/WBC)</p>
<p class="bl1">↑ levels seen w/ most types of hepatocellular injury; skeletal musc. injury, MI (AST &gt; ALT)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Alkaline phosphatase</b> (Aϕ): enzyme bound in hepatic canalicular membrane ↑ levels seen w/ biliary obstrxn or intrahepatic cholestasis also found in bone, intestines, kidney, placenta; confirm from liver w/: ↑ GGT (or ↑ 5′-NT)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bilirubin:</b> product of heme metab (unconjugated, “indirect”) carried by alb to liver where taken up for conjugation (“direct”) to make soluble, then excreted into bile.</p>
<p class="bl1">↑ direct hyperbili seen with cholestasis, enzymatic disorders (eg, Dubin-Johnson, Rotor’s)</p>
<p class="bl1">↑ indirect hyperbili seen with hemolysis, enzymatic disorders (eg, Crigler-Najjar, Gilbert’s)</p>
<p class="bl1">jaundice seen when bili &gt;2.5 mg/dL (esp. in sclera or under tongue); if hyperbili conjugated then ↑ urine bilirubin</p>
<p class="h2a">Tests of hepatic function</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Albumin:</b> marker for liver protein synthesis, ↓ slowly in liver failure (t<sub class="calibre8">1/2</sub> ~15–18 d)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prothrombin time</b> (PT): depends on synthesis of coag factors by liver (except FVIII); b/c t½ of some factors (eg, V, VII) is short, ↑ PT can occur w/in hrs of liver dysfxn</p>
<p class="image1"><img src="../images/00053.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">R-value</b> = ratio of ALT:Aϕ normalized to ULN for each = (ALT/ULN) ÷ (Aϕ/ULN)</p>
<p class="bl1">R &gt;5 suggests hepatocellular injury, &lt;2 suggests cholestatic injury, 2–5 suggests mixed</p>
<p class="capf"><b class="calibre4">Figure 3-3</b> Approach to abnormal liver tests with hepatocellular pattern</p>
<p class="image"><img src="../images/00054.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Workup for <i class="calibre3">acute</i> enzyme elevation</b> (often symptomatic)</p>
<p class="bl1">Severe ALT &amp; AST elevation (&gt;1000):</p>
<p class="bl2"><i class="calibre3">toxins</i> (usu. acetaminophen) → ✔ tox screen, EtOH, acet. levels. Other toxins: INH, disulfiram, pyrazinamide, OTC/herbal, fenofibrate, niacin, amiodarone, MDMA.</p>
<p class="bl2"><i class="calibre3">ischemia</i> (eg, sepsis, hypotension, Budd Chiari) → ✔ liver U/S w/ Doppler. Etiologies usually lead to ↑ LDH, ∴ usually ratio ALT:LDH &lt;1.5 (vs. &gt;1.5 w/ toxins, viruses).</p>
<p class="bl2"><i class="calibre3">viruses</i> (Hep A-E; HSV, CMV, VZV) → ✔ viral serologies</p>
<p class="bl2"><i class="calibre3">other</i> (AIH, acute Wilson Disease, acute biliary obstrxn) → see ALF &amp; cirrhosis sections</p>
<p class="bl1">Acute mild-moderate ALT &amp; AST elevation: as above, think meds/toxins (<i class="calibre3">see list at end of section</i>), viruses, ischemia/vascular issues in hospitalized Pts, obstruction (if mixed picture), systemic disease <span class="s1r">(<i class="calibre3">see “Workup for chronic enzyme elevation,”</i> below)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Workup for <i class="calibre3">chronic</i> enzyme elevation</b> (often asymptomatic)</p>
<p class="bl1">Screen for common causes: hep serologies, EtOH, liver U/S (? NAFLD, cirrhosis), meds</p>
<p class="bl1"><a id="page_3-16" class="calibre1"></a>If suspect underlying systemic disease: iron studies (HFE); ANA, ASMA, Ig levels (AIH); ceruloplasmin, urinary copper (Wilson); α1-AT (can cause liver dis even w/o lung involvement); celiac screening; thyroid studies; see “Cirrhosis”</p>
<p class="bl1">If ⊖ evaluation → lifestyle modification (wt loss, DM control) &amp; repeat testing 3–6 mo</p>
<p class="bl1">If evidence of chronic liver disease or persistent lab abnl, consider liver bx</p>
<p class="capf"><b class="calibre4">Figure 3-4</b> Approach to abnormal liver tests with cholestatic pattern</p>
<p class="image"><img src="../images/00055.jpeg" alt="" class="calibre2"/></p>
<p class="capf"><b class="calibre4">Figure 3-5</b> Approach to abnormal liver tests with infiltrative pattern</p>
<p class="image"><img src="../images/00056.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Common medications that cause abnormal liver tests <span class="s"><i class="calibre3">(<a href="http://livertox.nlm.nih.gov" class="calibre1">http://livertox.nlm.nih.gov</a>)</i></span></p>
<p class="image1"><img src="../images/00057.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="h48" class="calibre7"></a><a id="page_3-17" class="calibre7"></a><a href="part0002.html#rh54" class="calibre7">HEPATITIS</a></h2>
<p class="h">V<small class="calibre30">IRAL</small></p>
<p class="h2a">Hepatitis A <span class="s2">(ssRNA; 30–45% of acute viral hepatitis in U.S.;</span> <span class="s"><i class="calibre3">MMWR</i> 2018;67:1208</span><span class="s2">)</span></p>
<p class="bl"><span class="sbl">•</span> Transmission &amp; RFs: fecal–oral route; contam. food, water, shellfish; daycare ctr; intl travel</p>
<p class="bl"><span class="sbl">•</span> Incubation: 2–6 wk; no chronic carrier state</p>
<p class="bl"><span class="sbl">•</span> Sx: ↓ appetite, malaise, fever, N/V, RUQ pain, jaundice; rarely ALF (↑ w/ chronic HCV)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: acute hepatitis = ⊕ IgM anti-HAV; past exposure = ⊕ IgG anti-HAV (⊖IgM)</p>
<p class="bl"><span class="sbl">•</span> Rx for acute HAV: supportive care; refer to liver txplnt center if acute liver failure</p>
<p class="bl"><span class="sbl">•</span> Postexposure ppx: age 1–40 y → vaccine; age &lt;1 y or &gt;40 y, immunosupp, liver dis. → Ig</p>
<p class="h2a">Hepatitis B <span class="s2">(dsDNA; ~45% of acute viral hepatitis in U.S.;</span> <span class="s"><i class="calibre3">JAMA</i> 2018;319:1802</span><span class="s2">)</span></p>
<p class="bl"><span class="sbl">•</span> Transmission: blood (IVDU, transfusion), sexual, perinatal</p>
<p class="bl"><span class="sbl">•</span> Incubation: 6 wk–6 mo (mean 12–14 wk)</p>
<p class="bl"><span class="sbl">•</span> Acute infxn: 70% subclinical, 30% jaundice, &lt;1% acute liver failure (up to 60% mortality)</p>
<p class="bl"><span class="sbl">•</span> Chronic infxn: HBsAg ⊕ &gt;6 mo in &lt;5% of adult-acquired (↑ if immunosupp), &gt;90% of perinatal; ~40% chronic HBV → cirrhosis (↑ risk w/ HCV, HDV, or HIV coinfxn, EtOH)</p>
<p class="bl"><span class="sbl">•</span> HCC: ↑ risk if cirrhotic, ⊕ FHx HCC, African &gt;20 y old, Asian ♂ &gt;40 y old or ♀ &gt;50 y old, or &gt;40 y old w/ ↑ ALT ± HBV DNA &gt;2000. Screen w/ AFP &amp; U/S q6mo.</p>
<p class="bl"><span class="sbl">•</span> Extrahepatic syndromes: PAN (&lt;1%), membranous nephropathy, MPGN, arthritis</p>
<p class="bl"><span class="sbl">•</span> Serologic and virologic tests (see <i class="calibre3">Annals</i> 2017;167:794 for screening guidelines)</p>
<p class="bl1">HBsAg: appears before sx; used to screen blood donors; persists &gt;6 mo = chronic HBV</p>
<p class="bl1">HBeAg: evidence of viral replication and ↑ infectivity</p>
<p class="bl1">IgM anti-HBc: 1<sup class="calibre15">st</sup> Ab to appear; indicates acute infection window period = HBsAg becomes ⊖, anti-HBs not yet ⊕, anti-HBc only clue to infxn</p>
<p class="bl1">IgG anti-HBc: indicates previous (HBsAg ⊖) or ongoing (HBsAg ⊕) HBV infection</p>
<p class="bl1">anti-HBe: indicates waning viral replication, ↓ infectivity</p>
<p class="bl1">anti-HBs: indicates resolution of acute disease &amp; immunity (sole marker after vaccination)</p>
<p class="bl1">HBV DNA: presence in serum correlates w/ active viral replication in liver</p>
<p class="imagef"><img src="../images/00058.jpeg" alt="" class="calibre2"/></p>
<p class="fn">*Precore mutant: HBeAg not made, but anti-HBe can develop due to x-reactivity w/ HBcAg; a/w ↑ HBV DNA</p>
<p class="bl"><span class="sbl">•</span> Rx for acute HBV: supportive; hospitalize for Δ MS or ↑ INR (liver transplant center); consider antiviral therapy if severe</p>
<p class="imagef"><img src="../images/00059.jpeg" alt="" class="calibre2"/></p>
<p class="fn1">*ALT ULN &lt;30 U/L for ♂, &lt;19 U/L for ♂. Adapted from <i class="calibre3">Hepatology</i> 2016;63:261.</p>
<p class="fn">5<sup class="calibre35">th</sup> phase: chronic HBsAg ⊖ HBV infxn: HBeAg ⊖, anti-HBs ± ALT nl, “occult” HBV</p>
<p class="bl"><span class="sbl">•</span> Rx of chronic HBV: Rx in immune active or immune reactivation phases or cirrhotics w/ elevated HBV DNA or decomp. Consider liver bx if ALT 1–2× ULN or in immune tolerant phase if age &gt;40 y; Rx if mod-to-severe inflammation or fibrosis on bx.</p>
<p class="bl"><a id="page_3-18" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Entecavir</b> or <b class="calibre4">tenofovir:</b> nucleo(s/t)ide analogs, well tolerated, low resistance; at 5 y, HBeAg seroconversion is 30–40% &amp; loss of HBsAg is 5–10% <span class="s1r">(<i class="calibre3">Dig Dis Sci</i> 2015;60:1457; <i class="calibre3">Gastro Hep</i> 2016;1:185)</span>. Tenofovir preferred if h/o lamivudine resistance.</p>
<p class="bl"><span class="sbl">•</span> Rx duration: (1) HBeAg ⊕ immune active w/o cirrhosis: if seroconversion (HBeAg ⊖, anti-HBe ⊕), can stop after 1 y if ALT nl &amp; HBV DNA suppressed or until HBsAg clears; (2) HBeAg ⊖ immune reactivation: indefinite; (3) cirrhotic: indefinite</p>
<p class="bl"><span class="sbl">•</span> If undergo liver transplant: HBIG + nucleo(s/t)ide analogue effective in preventing reinfection</p>
<p class="bl"><span class="sbl">•</span> HIV/HBV <i class="calibre3">coinfection:</i> Rx w/ 2 drugs active against both HBV &amp; HIV (<a href="https://aidsinfo.nih.gov" class="calibre1">https://aidsinfo.nih.gov</a>)</p>
<p class="bl"><span class="sbl">•</span> Immunosuppression: prior to initiating chemoRx, anti-TNF, rituximab, steroids (&gt;20 mg/d &gt; 1 mo), screen for HBV; Rx if mod-to-high risk of reactive. (incl HBsAb ⊕ getting rituximab)</p>
<p class="bl"><span class="sbl">•</span> Postexposure (risk infxn ~30%) ppx: HBIG → vaccine (if unvac or known nonresponder)</p>
<p class="h2a">Hepatitis C <span class="s2">(ssRNA; ~</span>1<span class="s2">0% of acute viral hepatitis in U.S.;</span> <span class="s"><i class="calibre3">Lancet</i> 2015;385:1124</span><span class="s2">)</span></p>
<p class="bl"><span class="sbl">•</span> Transmission: blood (IVDU, transfusion rare cause) &gt; sexual; 20–30% w/o clear precipitant</p>
<p class="bl"><span class="sbl">•</span> Incubation: 1–5 mo; mean 6–7 wk</p>
<p class="bl"><span class="sbl">•</span> Acute infxn: 80% subclinical; 10–20% sx hepatitis w/ jaundice; acute liver failure rare; prob of spont clearance a/w <i class="calibre3">IL28B</i> &amp; HLA class II genotypes <span class="s1r">(<i class="calibre3">Annals</i> 2013;158:235)</span></p>
<p class="bl"><span class="sbl">•</span> Chronic: up to 85% → chronic hepatitis, 20–30% of whom develop cirrhosis (after ~20 y)</p>
<p class="bl1">↑ risk of cirrhosis in men, EtOH, HIV; HCC in 1–4% of cirrhotics/y</p>
<p class="bl"><span class="sbl">•</span> Extrahepatic syndromes: mixed cryoglobulinemia, porphyria cutanea tarda, lichen planus, leukocytoclastic vasculitis, thyroiditis, MPGN, IPF, NHL and monoclonal gammopathies</p>
<p class="bl"><span class="sbl">•</span> Serologic, virologic, &amp; genetic tests</p>
<p class="bl1">anti-HCV (ELISA): ⊕ in 6 wk, does <i class="calibre3">not</i> = recovery or immunity; can be ⊖ after recovery</p>
<p class="bl1">HCV RNA: ⊕ w/in 2 wk, marker of active infection</p>
<p class="bl1">HCV genotype (1–6): guides duration &amp; predicts response to Rx; geno. 3 a/w ↑ risk HCC</p>
<p class="bl"><span class="sbl">•</span> Dx: <i class="calibre3">acute</i> hepatitis = ⊕ HCV RNA, ± anti-HCV; <i class="calibre3">resolved</i> = ⊖ HCV RNA, ± anti-HCV; <i class="calibre3">chronic</i> = ⊕ HCV RNA, ⊕ anti-HCV</p>
<p class="bl"><span class="sbl">•</span> Treatment indications (<span class="underline"><a href="http://www.hcvguidelines.org" class="calibre1">www.hcvguidelines.org</a></span>) <span class="s1r">(<i class="calibre3">Hep</i> 2018;68:827; <i class="calibre3">Lancet</i> 2019;393:1453)</span></p>
<p class="bl1">Acute: if no spont. clearance at 12–16 wk, can Rx w/ same regimens for chronic HCV</p>
<p class="bl1">Chronic: ↓ HCC &amp; mortality. Recommended for all except if ↓ life expectancy.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre36"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Recommended Oral Direct-Acting Antiviral (DAA) Regimens</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead">Regimen</p></td>
<td class="bg0-b"><p class="tabheadc">Indication</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">sofosbuvir &amp; ledipasvir</p></td>
<td class="bg0-b"><p class="tab">Genotypes 1 and 4</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">grazoprevir &amp; elbasvir</p></td>
<td class="bg0-b"><p class="tab">Genotypes 1 and 4</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">sofosbuvir &amp; daclatasvir</p></td>
<td class="bg0-b"><p class="tab">Alternative for genotypes 1–4</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">sofosbuvir &amp; velpatasvir</p></td>
<td class="bg0-b"><p class="tab">Genotypes 1–6</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">sofosbuvir, velpatasvir, &amp; voxilaprevir</p></td>
<td class="bg0-b"><p class="tab">DAA-experienced genotypes 1–6</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">glecaprevir &amp; pibrentasvir</p></td>
<td class="bg0-b"><p class="tab">Genotypes 1–6, DAA-experienced genotype 1</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab">Individual components: <i class="calibre3">RNA polymerase inhibitor</i> (“…buvir”); <i class="calibre3">NS5a inhibitor</i> (“…asvir”); <i class="calibre3">NS3/4A protease inhibitor</i> (“…previr”)</p></td>
</tr>
</table>
<p class="tsr">Based on the American Association for the Study of Liver Diseases/Infectious Diseases Society of America 2018 Guidance. <a href="http://www.hcvguidelines.org" class="calibre1">www.hcvguidelines.org</a>. <i class="calibre3">Clin Infect Dis</i> 2018;67:1477</p>
<p class="bl"><span class="sbl">•</span> Monitoring on Rx: CBC, INR, LFTs, GFR, HCV VL prior to starting Rx. PIs contraindicated if decomp. liver dx (ascites, encephalopathy) or CTP score ≥7. D/c Rx if jaundice, N/V, weakness, 10x ↑ in ALT, or significant ↑ in bili, Aϕ, INR after 4 wk.</p>
<p class="bl"><span class="sbl">•</span> Goal is <i class="calibre3">sustained virologic response</i> (SVR) = ∅ viremia 12 wk after completion of Rx. Success depends on genotype but SVR rates &gt;90% with current regimens.</p>
<p class="bl"><span class="sbl">•</span> Special populations (HCV/HIV coinfection, decompensated cirrhosis, s/p liver transplant, renal impairment): <a href="http://www.hcvguidelines.com" class="calibre1">www.hcvguidelines.com</a> for updated recs on mgmt</p>
<p class="bl"><span class="sbl">•</span> Vaccinate all chronic HCV patients against HBV and HAV if not immune</p>
<p class="bl"><span class="sbl">•</span> Postexposure (needlestick risk ~3%) ppx: none, although sofosbuvir-velpatasivir under investigation in clinical trial; if HCV RNA → ⊕, consider Rx w/in 3 mo</p>
<p class="h2a"><b class="calibre4">Hepatitis D</b> <span class="s2">(RNA)</span></p>
<p class="bl"><span class="sbl">•</span> Transmission: blood or sexual; endemic in Africa &amp; E. Europe. Generally requires host to already have HBV infxn in order to cause co-infection or superinfection; in rare cases (immunosupp s/p liver txplt) can replicate autonomously.</p>
<p class="bl"><span class="sbl">•</span> Natural hx: acute HBV-HDV coinfection resolves in &gt;80% of cases; however acute HDV superinfection leads to chronic HBV-HDV in most cases (↑ progression to cirrhosis, HCC)</p>
<p class="h2a">Hepatitis E <span class="s2">(ssRNA;</span> <span class="s"><i class="calibre3">World J Gastro</i> 2016;22:7030; <i class="calibre3">Gastro Clin N Am</i> 2017;46:393</span><span class="s2">)</span></p>
<p class="bl"><span class="sbl">•</span> Most common cause of acute viral hepatitis in endemic areas</p>
<p class="bl"><span class="sbl">•</span> Transmission: fecal–oral; travelers to central &amp; SE Asia, Africa and Mexico, exp. to swine. ↑ rates of cases in Europe.</p>
<p class="bl"><span class="sbl">•</span> Natural hx: acute hepatitis w/ ↑ mort. (10–20%) if pregnant; rare chronic in transplant Pts</p>
<p class="bl"><span class="sbl">•</span> Dx: IgM anti-HEV (through CDC), HEV RNA</p>
<p class="bl"><span class="sbl">•</span> Extrahepatic sx: arthritis, pancreatitis, anemia, neuro (GBS, meningoencephalitis)</p>
<p class="h2a">Other viruses <span class="s2">(human pegivirus, CMV, EBV, HSV, VZV)</span></p>
<p class="h"><a id="page_3-19" class="calibre7"></a>A<small class="calibre30">UTOIMMUNE</small> H<small class="calibre30">EPATITIS</small> (AIH)</p>
<p class="h2a">Classification <span class="s">(<i class="calibre3">J Hep</i> 2015;62:S100, <i class="calibre3">World J Gastro</i> 2015;21:60)</span></p>
<p class="bl"><span class="sbl">•</span> Type 1: anti-smooth muscle Ab (ASMA), ANA; anti-soluble liver antigen (anti-SLA), a/w more severe disease and relapsing disease</p>
<p class="bl"><span class="sbl">•</span> Type 2: anti-liver/kidney microsome 1 (anti-LKM1); anti-liver cytosol type 1 (ALC-1);</p>
<p class="bl"><span class="sbl">•</span> Overlap syndrome: AIH + PBC (suspect if ⊕ antimitochondrial Ab or ⊕ histology → “autoimmune cholangitis”) or PSC (suspect if ↑ Aφ, IBD, pruritus, or ⊕ radiology/histology)</p>
<p class="bl"><span class="sbl">•</span> Drug-induced: minocycline, nitrofurantoin, infliximab, hydralazine, α-methyldopa, statins</p>
<p class="h2a">Diagnosis and treatment <span class="s">(<i class="calibre3">J Hepatol</i> 2015;63:1543, <i class="calibre3">Clin Liver Dis</i> 2015;19:57)</span></p>
<p class="bl"><span class="sbl">•</span> 70% female; 40% present w/ severe AIH (3% ALF) w/ ALT &gt;10 × ULN; 34–45% asx</p>
<p class="bl"><span class="sbl">•</span> Extrahepatic syndromes: thyroiditis, arthritis, UC, Sjögren’s, Coombs’ ⊕ hemolytic anemia</p>
<p class="bl"><span class="sbl">•</span> Dx: scoring system combining serologies, ↑ IgG, ∅ viral hepatitis, &amp; liver bx (interface hepatitis &amp; lymphoplasmacytic infiltrate) has high Sp &amp; mod Se <span class="s1r">(<i class="calibre3">Dig Dis</i> 2015;33[S2]:53)</span></p>
<p class="bl"><span class="sbl">•</span> Rx: (1) ALT 10× ULN; (2) ALT 5× ULN &amp; IgG 2× ULN; or (3) bridging/multiacinar necrosis</p>
<p class="bl"><span class="sbl">•</span> Induction Rx: (1) prednisone monoRx; (2) prednisone + AZA, or (3) budesonide (if non-cirrhotic) + AZA → 65–80% remission (asx, nl LFTs, bili, &amp; IgG, none-to-minimal interface hepatitis); taper steroids as able; relapse rate of 50–80% <span class="s1r">(<i class="calibre3">J Hep</i> 2015;62:S100)</span></p>
<p class="bl"><span class="sbl">•</span> Nonresponders or AZA intolerant: cyclosporine, tacrolimus, MMF, rituximab, infliximab</p>
<p class="bl"><span class="sbl">•</span> HCC screening and liver transplant referral for ESLD</p>
<p class="h">O<small class="calibre30">THER</small> C<small class="calibre30">AUSES</small> <small class="calibre30">OF</small> H<small class="calibre30">EPATITIS</small> <small class="calibre30">OR</small> H<small class="calibre30">EPATOTOXICITY</small></p>
<p class="h2a">Alcoholic hepatitis <span class="s">(<i class="calibre3">J Hepatol</i> 2016;69:154; <i class="calibre3">Am J Gastro</i> 2018;113:175)</span></p>
<p class="bl"><span class="sbl">•</span> Sx: progressive jaundice, tender hepatomegaly, fever, ascites, GIB, encephalopathy</p>
<p class="bl"><span class="sbl">•</span> Labs: ALT usually &lt;300–500 w/ AST:ALT &gt; 2:1, ↓ plt, ↑ Tbili &amp; INR indicate severe hepatitis</p>
<p class="bl"><span class="sbl">•</span> Prognosis: scoring systems include Maddrey’s discriminant fxn (MDF), Lille model, MELD</p>
<p class="bl1">MDF (4.6 × [PT – control] + Tb) ≥32 w/ 30–50% 1-mo mortality if unRx’d <span class="s1r">(<i class="calibre3">Gastro</i> 1996;110:1847)</span></p>
<p class="bl1">Lille model: predicts nonresponse to steroids after 1<sup class="calibre15">st</sup> week of Rx; score &gt;0.45 predicts poor response to further steroid Rx and a/w ↓ in 6-mo survival <span class="s1r">(<i class="calibre3">Hep</i> 2007;45:1348)</span></p>
<p class="bl1">Combination of Lille + MELD scores best predictor of mortality <span class="s1r">(<i class="calibre3">Gastro</i> 2015;149:398)</span></p>
<p class="bl"><span class="sbl">•</span> Rx: consider if MDF ≥32, MELD &gt;18, or presence of encephalopathy</p>
<p class="bl1">Steroids (eg, methylprednisolone 32 mg/d or prednisolone 40 mg/d × 4 wk → 4–6 wk taper) may ↓ 1-mo but not 6-mo mortality, a/w ↑ infection <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:1619, CD001511)</span></p>
<p class="bl1">Contraindic.: active GIB, pancreatitis, untreated HBV, uncontrolled bact/fungal/TB infxn</p>
<p class="bl1">Addition of NAC to steroids ↓ 1-mo but not 6-mo mortality <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:1781)</span></p>
<p class="bl"><span class="sbl">•</span> Consider early transplantation in carefully selected Pts <span class="s1r">(<i class="calibre3">Gastro</i> 2018;155:422)</span></p>
<p class="h2a">Acetaminophen hepatotoxicity <span class="s"><i class="calibre3">(Clin J Transl Hepatol</i> 2016;4:131; <i class="calibre3">BMJ</i> 2016;353:i2579)</span></p>
<p class="bl"><span class="sbl">•</span> Pathophysiology: &gt;90% of acetaminophen (N-acetyl-p-aminophenol, APAP) metab into nontoxic metab, but ~5% metab by CYP2E1 into NAPQI, a hepatotoxic metab detoxified by glutathione conjugation; APAP overdose (&gt;10 g) depletes glutathione stores → injury</p>
<p class="bl"><span class="sbl">•</span> CYP2E1 <i class="calibre3">induced</i> by fasting, alcohol, and certain anticonvulsants and anti-TB drugs, resulting in a “therapeutic misadventure” with even low doses (2–6 g) of acetaminophen</p>
<p class="bl"><span class="sbl">•</span> Liver dysfunction may not be apparent for 2–6 d</p>
<p class="bl"><span class="sbl">•</span> Rx: NG lavage, activated charcoal if w/in 4 h. Consider early transfer to transplant ctr</p>
<p class="bl1"><b class="calibre4"><i class="calibre3">N</i>-acetylcysteine:</b> administer up to 72 h after ingestion, if time of ingestion unknown or chronic ingestion &gt;4g/d; low threshold to start NAC w/ low or undetectable APAP levels</p>
<p class="bl1">PO NAC (preferred): 140 mg/kg loading dose → 70 mg/kg q4h × 17 additional doses</p>
<p class="bl1">IV NAC: 150 mg/kg × 1 h → 50 mg/kg × 4 h → 100 mg/kg × 16 h; risk of anaphylaxis (↓ w/ 12-h regimen; <i class="calibre3">Lancet</i> 2014;383:697); use if unable to tolerate POs, GIB, pregnancy, ALF</p>
<p class="h2a">Ischemic hepatitis</p>
<p class="bl"><span class="sbl">•</span> “Shock liver” w/ AST &amp; ALT &gt;1000 + ↑↑ LDH (ALT:LDH ratio often &lt;1.5); delayed ↑↑ Tbili</p>
<p class="bl"><span class="sbl">•</span> Seen in HoTN &amp; CHF; often requires ↑ venous + ↓ portal/arterial pressure + hypoxia</p>
<p class="h2a">Nonalcoholic fatty liver disease (NAFLD) <span class="s">(<i class="calibre3">NEJM</i> 2017;377:2063)</span></p>
<p class="bl"><span class="sbl">•</span> Definition: fatty infiltration of liver <i class="calibre3">and</i> absence of EtOH or other cause of steatosis</p>
<p class="bl1"><b class="calibre4">NAFL</b> = steatosis, ∅ inflam; <b class="calibre4">NASH</b> = steatosis + inflam ± fibrosis on bx</p>
<p class="bl"><span class="sbl">•</span> NAFLD: 10–30% of U.S. pop. &amp; over 60% in T2DM &amp; obesity</p>
<p class="bl"><span class="sbl">•</span> NASH: 2–5% of NAFLD &amp; risk of cirrhosis in NASH w/ fibrosis on bx is 30% at 10 y</p>
<p class="bl"><span class="sbl">•</span> Clinical: 80% asx, ↑ ALT &gt; AST, but nl ALT/AST does not exclude poss. of NASH on bx</p>
<p class="bl"><span class="sbl">•</span> Dx: liver bx remains gold standard. VCT elastography emerging modality <span class="s1r">(<i class="calibre3">J Hepatol</i> 2017;66:1022)</span>. NAFLD fibrosis score predicts NASH w/ advanced fibrosis with PPV &gt;80%</p>
<p class="bl"><span class="sbl">•</span> Rx: wt loss (ideally ≥10% to reverse fibrosis, <i class="calibre3">Gastro</i> 2015;149:367), exercise, DM control, liraglutide <span class="s1r">(<i class="calibre3">Lancet</i> 2016;387:679)</span> or pioglitazone (even w/o DM), statins <span class="s1r">(<i class="calibre3">Metabolism</i> 2017;71:17)</span>; vit E ↓ steatosis but not fibrosis in Pts w/o DM <span class="s1r">(<i class="calibre3">Hepatol</i> 2018;67:328)</span></p>
<p class="bl"><span class="sbl">•</span> HCC a complication of NAFLD, usually but not always in setting of NASH cirrhosis</p>
<h2 class="ct"><a id="h49" class="calibre7"></a><a id="page_3-20" class="calibre7"></a><a href="part0002.html#rh55" class="calibre7">ACUTE LIVER FAILURE (ALF)</a></h2>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Acute insult to liver + coagulopathy + encephalopathy; most w/o known preexisting liver dis.</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Hyperacute</i> if encephalopathy &lt;7 d from jaundice onset; <i class="calibre3">acute</i> if 7–21 d, <i class="calibre3">subacute</i> if &gt;21 d</p>
<p class="bl"><span class="sbl">•</span> Acute on chronic liver failure: acute insult to liver in Pt w/ underlying chronic liver disease</p>
<p class="h2a">Etiology <span class="s">(<i class="calibre3">J Hepatol</i> 2015;62:S112)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drugs</b>/<b class="calibre4">toxins</b> (nearly 80% of cases in U.S.; <i class="calibre3">Gastro</i> 2015;148:1353, <i class="calibre3">Clin Liver Dis</i> 2017;21:151)</p>
<p class="bl1">Drugs: acetaminophen (most common cause; &gt;40% of all cases in U.S., typically unintentional overdose); anti-TB drugs (INH, rifampin, pyrazinamide); AEDs (phenytoin, valproate, carbamazepine); NSAIDs (idiosyncratic, not dose related); abx (eg, fluoroquinolones, macrolides); MDMA (ecstasy)</p>
<p class="bl1">Toxins: <i class="calibre3">Amanita phalloides</i> (mushroom sp. in West Coast), certain herbal preparations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Viral</b> (12% of cases in the U.S.): HAV, HBV, HCV (rare), HDV + HBV, HEV (esp. if pregnant). In immunosupp: HSV (50% have skin lesions), EBV, VZV, CMV, HHV6</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vascular:</b> Budd-Chiari, ischemic hepatitis, hepatic sinusoidal obstructive syndrome</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Other:</b> Wilson disease, pregnancy-related ALF (acute fatty liver, preeclampsia, HELLP), initial presentation of autoimmune hepatitis; idiopathic</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Initial presentation usually nonspecific: n/v, malaise; then jaundice &amp; multiorgan failure</p>
<p class="bl"><span class="sbl">•</span> Neurologic: <b class="calibre4">encephalopathy:</b> grade 1 = attn deficit, tremor; grade 2 = <i class="calibre3">asterixis</i>, lethargy, confusion, ataxia; grade 3 = somnolence, rigidity, clonus, hyporeflexia; grade 4 = coma</p>
<p class="bl1"><b class="calibre4">cerebral edema:</b> astrocyte swelling likely related to ↑ ammonia levels</p>
<p class="bl"><span class="sbl">•</span> Cardiovascular: <b class="calibre4">hypotension</b> with low SVR, shock</p>
<p class="bl"><span class="sbl">•</span> Pulmonary: <b class="calibre4">respiratory alkalosis</b>, impaired peripheral O<sub class="calibre8">2</sub> uptake, pulm edema, ARDS</p>
<p class="bl"><span class="sbl">•</span> GI: bleeding (due to bleeding diathesis), pancreatitis (? due to ischemia, drugs, infxn)</p>
<p class="bl"><span class="sbl">•</span> Renal: ATN, <b class="calibre4">hepatorenal syndrome</b>, hyponatremia, hypokalemia, hypophosphatemia</p>
<p class="bl"><span class="sbl">•</span> Hematology: thrombocytopenia, ↑ PT/PTT, ↓ fibrinogen, <b class="calibre4">bleeding diathesis</b> (↓ synthesis of coag factors balanced by ↓ protein C/S; bleeding mostly due to low platelet count), DIC</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infection</b> (~90% of Pts): espec. with <i class="calibre3">Staph</i>, <i class="calibre3">Strep</i>, GNRs and fungi (↓ immune fxn, invasive procedures); SBP in 32% of Pts; <i class="calibre3">fever and</i> ↑ <i class="calibre3">WBC may be absent</i></p>
<p class="bl"><span class="sbl">•</span> Endocrine: <b class="calibre4">hypoglycemia</b> (↓ glc synthesis), metabolic acidosis (↑ lactate), adrenal insuf.</p>
<p class="h2a">Workup <span class="s">(<i class="calibre3">Clin Liver Dis</i> 2017;21:769)</span></p>
<p class="bl"><span class="sbl">•</span> CBC, PT/PTT, LFTs, lytes, BUN/Cr, NH<sub class="calibre8">3</sub>, pH, <i class="calibre3">arterial</i> lactate, acetaminophen level, HIV, amylase/lipase, viral serologies (qv) in all Pts, with additional labs as below if suspected</p>
<p class="bl"><span class="sbl">•</span> Autoimmune hep serologies &amp; IgG levels, ceruloplasmin &amp; serum/urine copper, preg test</p>
<p class="bl"><span class="sbl">•</span> Imaging studies (RUQ U/S or abd CT, Doppler studies of portal and hepatic veins)</p>
<p class="bl"><span class="sbl">•</span> Liver biopsy if underlying etiology remains elusive after initial testing</p>
<p class="h2a">Management <span class="s">(<i class="calibre3">J Clin Exp Hepatol</i> 2015;5:S104)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ICU care at liver transplant center</b> for hemodynamic &amp; ventilatory support; CVVH for AKI</p>
<p class="bl"><span class="sbl">•</span> Early listing for liver transplantation in selected Pts (see below)</p>
<p class="bl"><span class="sbl">•</span> Cerebral edema: consider ICP monitoring if grade 3/4 enceph; if ↑ ICP → mannitol 0.5–1.0 mg/kg; if arterial NH<sub class="calibre8">3</sub> &gt;150, grade 3/4 enceph, AKI or on vasopressors → prophylactic 3% saline for goal Na 145–155 mEq/L; barbiturates &amp; hypothermia if refractory ↑ ICP</p>
<p class="bl"><span class="sbl">•</span> Encephalopathy: intubate for grade 3 or 4; lactulose is of little benefit &amp; may be detrimental</p>
<p class="bl"><span class="sbl">•</span> Coagulopathy: vit K, FFP/plts/cryo if active bleeding or before invasive procedure; PPI ppx</p>
<p class="bl"><span class="sbl">•</span> Infection: low threshold for abx (broad spectrum, eg, vancomycin &amp; 3<sup class="calibre15">rd</sup>-gen ceph.) if suspect infection; anti-fungal coverage in high-risk Pts</p>
<p class="bl"><span class="sbl">•</span> Rx of specific causes: NAC if acetaminophen; antiviral for HBV; plasma exchange can be temporizing measure for Wilson disease; IV acyclovir for HSV; PCN-G for <i class="calibre3">A. phalloides;</i> delivery of child for pregnancy-related; TIPS, anticoag for Budd-Chiari. Lack of data for use of steroids in autoimmune, but often given <span class="s1r">(<i class="calibre3">Hepatology</i> 2014;59:612)</span>.</p>
<p class="bl"><span class="sbl">•</span> NAC may benefit pts w/ non-APAP ALF but data inconclusive <span class="s1r">(<i class="calibre3">Clin Drug Investig</i> 2017;37:473)</span></p>
<p class="bl"><span class="sbl">•</span> Liver Tx if poor prog. but could survive surg. Extracorp liver support (molec. adsorbent recirc. system, MARS) &amp; high-volume plasma exchange being studied <span class="s1r">(<i class="calibre3">J Hepatol</i> 2016;64:69)</span>.</p>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">Ann Intern Med</i> 2016;164:724; <i class="calibre3">World J Gastro</i> 2016;22:1523)</span></p>
<p class="bl"><span class="sbl">•</span> Non-acetaminophen ALF mortality ~70%, acetaminophen-induced ALF mortality ~25–30%</p>
<p class="bl"><span class="sbl">•</span> Predictors of poor outcome (King’s College Hospital, UK):</p>
<p class="bl1">Acetaminophen-induced: pH &lt;7.25, INR &gt;6.5 or PT&gt;100, Cr &gt;3.4, or grade 3/4 enceph.</p>
<p class="bl1">Non-acetamin.-induced: INR &gt;6.5 or PT&gt;100; <i class="calibre3">or</i> ≥3 of the following: unfavorable etiology (seronegative hepatitis or drug reaction); age &lt;10 or &gt;40 y; INR &gt;3.5 or PT &gt;50; Tbili &gt;17.5; duration of jaundice &gt;7 d prior to onset of encephalopathy</p>
<p class="bl"><span class="sbl">•</span> ~20–25% of Pts undergo liver transplantation w/ 5-y survival rate of 75%</p>
<p class="bl"><span class="sbl">•</span> BMI &gt;30, Cr &gt;2, age &gt;50 y, pressors/vent support a/w poorer acute transplant outcome</p>
<h2 class="ct"><a id="h50" class="calibre7"></a><a id="page_3-21" class="calibre7"></a><a href="part0002.html#rh56" class="calibre7">CIRRHOSIS</a></h2>
<p class="h2a">Definition <span class="s">(<i class="calibre3">Dig Dis</i> 2016;34:374; <i class="calibre3">NEJM</i> 2016;375:767; <i class="calibre3">J Hep</i> 2016;64:717)</span></p><p class="bl"><span class="sbl">•</span> Definition: <b class="calibre4">fibrosis and regenerative nodules</b> resulting from hepatocellular injury</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Decompensated</b> = jaundice, variceal bleed, encephalopathy, ascites; worse prognosis</p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Alcohol</b> (~60–70%) and other toxins (eg, arsenic)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Viral hepatitis</b> (~10%): chronic HBV, HCV, HDV infection</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Autoimmune hepatitis:</b> ♀, ↑ IgG, ⊕ ANA, antismooth muscle Ab, anti-LKM-1, anti-LC1</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Metabolic diseases</b> (~5%): hemochromatosis, Wilson disease, α<sub class="calibre8">1</sub>-AT deficiency</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biliary tract diseases</b> (~5%): primary biliary cholangitis, secondary biliary cirrhosis (calculus, neoplasm, stricture, biliary atresia), primary sclerosing cholangitis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vascular diseases:</b> Budd-Chiari syndrome, R-sided CHF, constrictive pericarditis, SOS</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonalcoholic fatty liver dis. (NAFLD</b>, 10–15%) cause of most “cryptogenic cirrhosis”</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Medications:</b> amiodarone, methotrexate, vitamin A, valproate acid, isoniazid</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Nonspecific sx (anorexia, fatigue) or jaundice, encephalopathy, ascites, variceal bleeding</p>
<p class="h2a">Physical exam</p>
<p class="bl"><span class="sbl">•</span> Liver: <i class="calibre3">initially</i> enlarged, palpable (L lobe predom), firm; <i class="calibre3">eventually</i> shrunken, nodular</p>
<p class="bl"><span class="sbl">•</span> Signs of liver failure: jaundice (bili &gt;2.5), spider angiomata &amp; palmar erythema (↑ estra- diol), Dupuytren’s contractures, white nail lines (Muehrcke’s lines) &amp; proximal nail beds (Terry’s nails), ↑ parotid &amp; lacrimal glands, gynecomastia, testicular atrophy, asterixis, encephalopathy, fetor hepaticus, clubbing, hypertrophic osteoarthropathy</p>
<p class="bl"><span class="sbl">•</span> Signs of portal hypertension: splenomegaly, ascites, dilated superficial abdominal veins (caput medusae), epigastric Cruveilhier-Baumgarten venous hum</p>
<p class="h2a">Laboratory studies</p>
<p class="bl"><span class="sbl">•</span> LFTs: ↑ <b class="calibre4">bili</b>, ↑ <b class="calibre4">PT/INR</b> (poor correlation w/ bleeding; factor VIII nl b/c not synthesized by liver), ↓ <b class="calibre4">alb</b>, ± ↑ aminotransferases (AST &gt; ALT if late) and ↑ Aϕ (variable)</p>
<p class="bl"><span class="sbl">•</span> Hematologic tests: anemia (marrow suppress., hypersplenism, Fe ± folate defic.), neutro-penia (hypersplenism), thrombocytopenia (hypersplenism, ↓ Tpo production, EtOH tox)</p>
<p class="bl"><span class="sbl">•</span> Chem: ↓ Na (↑ ADH due to ↓ EAV); ↑ Fe/TIBC, ↑ ferritin (released from hepatocytes)</p>
<p class="bl"><span class="sbl">•</span> Lab indices predictive of cirrhosis: AST/plt &gt;2; Lok index; Bonacini score <span class="s1r">(<i class="calibre3">JAMA</i> 2012;307:832)</span></p>
<p class="bl"><span class="sbl">•</span> Indirect markers of fibrosis: FibroTest/FibroSURE (HBV/HCV), FIB-4 index (NAFLD, HCV), NAFLD fibrosis score</p>
<p class="h2a">Workup <span class="s">(<i class="calibre3">Lancet</i> 2014;383:1749; <i class="calibre3">Am J Gastro</i> 2017;112:18)</span></p>
<p class="bl"><span class="sbl">•</span> Abd <b class="calibre4">U/S w/ Doppler:</b> liver size &amp; echotexture, r/o HCC, ascites, ✔ patency of vasculature</p>
<p class="bl"><span class="sbl">•</span> Determine etiology: hepatitis serologies (HBsAg, anti-HBs, anti-HCV), autoimmune hepatitis studies (IgG, ANA, anti–smooth muscle Ab), Fe and Cu studies, α<sub class="calibre8">1</sub>-AT, AMA</p>
<p class="bl"><span class="sbl">•</span> Assess fibrosis: biomarkers (FibroSURE = panel of 5 markers validated in HCV, ↑ score predictive of fibrosis); elastography (U/S or MR-based; measurement of liver stiffness)</p>
<p class="bl"><span class="sbl">•</span> Liver bx (gold standard): percutaneous or transjugular (consider if ascites or coagulopathy), used to confirm presence of cirrhosis and dx etiology</p>
<p class="h2a">Prognosis <span class="s2">(<a href="http://www.mdcalc.com/child-pugh-score-cirrhosis-mortality" class="calibre1">www.mdcalc.com/child-pugh-score-cirrhosis-mortality</a>)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Modified Child-Turcotte-Pugh (CPS)</b> score based on ascites, enceph., &amp; labs (bili, alb &amp; INR; see Appendix). CPS A (5-6 pts): 1-y survival 100%, B (7–9): 80%; C (10–15): 45%.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MELD-Na</b> (<b class="calibre4">M</b>odel for <b class="calibre4">E</b>nd-Stage <b class="calibre4">L</b>iver <b class="calibre4">D</b>isease; <i class="calibre3">Gastro</i> 2011;14:1952): used to stratify liver Tx list &amp; predict 3-mo survival in cirrhosis and some acute forms of liver dis. Based on Cr, INR, total bili, Na. Calculator: <a href="https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/" class="calibre1">https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/</a>.</p>
<p class="bl1">If MELD &lt;21, additional predictors of mortality include refractory ascites, ↑ HVPG &amp; ↓ QoL.</p>
<p class="bl1">MELD-Plus includes alb, chol, LOS, age, WBC <span class="s1r">(<i class="calibre3">PLOS One</i> 2017;12:e0186301)</span>.</p>
<p class="h2a">Ascites <span class="s2">(see “Ascites” for diagnostic eval;</span> <span class="s"><i class="calibre3">Liver Int</i> 2016;36:S1:109; <i class="calibre3">Dig Dis</i> 2017;35:402</span><span class="s2">)</span></p>
<p class="bl"><span class="sbl">•</span> Due to portal HTN (defined as hepatic venous pressure gradient [HVPG] &gt;5 mmHg)</p>
<p class="bl"><span class="sbl">•</span> Develops in 60% w/in 10 y; ~50% mortality at 5 y</p>
<p class="bl"><span class="sbl">•</span> Treatment: ↓ <b class="calibre4">Na intake</b> (1–2 g/d); restrict intake of free water if Na &lt;125</p>
<p class="bl1"><b class="calibre4">Diuretics:</b> goal diurese ~1 L/d. Use spironolactone ± furosemide in 5:2 ratio (eg, 100 &amp; 40 mg daily); urine Na/K &gt;1 implies effective natriuresis if Pt compliant w/ low-Na diet</p>
<p class="bl1">Avoid NSAIDs in cirrhosis because interfere w/ diuretic action and are nephrotoxic</p>
<p class="bl1">Albumin (40 g 2×/wk × 2 wk, then weekly × 16 wk) ↓ mortality 38% <span class="s1r">(<i class="calibre3">Lancet</i> 2018;391:2417)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Refractory ascites:</b> seen in 5–10% of Pts; 2-y survival 25%</p>
<p class="bl1">Diuretic-resistant on 2-g Na diet, minimal weight loss on maximal diuretic doses, or diuretic-induced complications (AKI, Na &lt;125, ↑ K, encephalopathy)</p>
<p class="bl1"><a id="page_3-22" class="calibre1"></a>Conflicting evid. for d/c’ing βB <span class="s1r">(<i class="calibre3">Hep</i> 2016;63:1968; <i class="calibre3">J Hepatol</i> 2016;64:574)</span>. Especially consider if SBP &lt;90 or MAP ≤82 mmHg, serum Na &lt;120 mEq/L, AKI, HRS, SBP, sepsis, severe alcoholic hepatitis, poor follow-up. If limited by HoTN, can add midodrine.</p>
<p class="bl1"><b class="calibre4">Large-volume paracenteses</b> (LVP; &gt;5 L fluid removal): give 6–8 g albumin per L fluid removed (above 5 L) as colloid replacement a/w ↓ risk of post-para circulatory dysfxn &amp; possibly ↓ mortality <span class="s1r">(<i class="calibre3">Hep</i> 2012;55:1172)</span>. Avoid LVP if SBP present because ↑ risk of AKI.</p>
<p class="bl1"><b class="calibre4">Transjugular intrahepatic portosystemic shunt</b> (TIPS) <span class="s1r">(<i class="calibre3">Gastro</i> 2017;152:157)</span></p>
<p class="bl2">↓ ascites in 75%; ↑ CrCl, ↑ enceph, survival benefit over LVP remains controversial</p>
<p class="bl2">Contraindic: grade II enceph, CHF or pulm HTN, active infxn or biliary obstruction</p>
<p class="bl2">Complications: bleeding, fistula; stent thrombosis (1-y patency w/ coated stents ~80%); infxn (“endotipsitis”); new or ↑ enceph in 20–30% <span class="s1r">(<i class="calibre3">Am J Gastro</i> 2016;111:523)</span>, hemolysis</p>
<p class="bl1">Consider for liver transplant if above fail</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hepatic hydrothorax:</b> 2° diaphragmatic defect; often unilateral, R &gt; L, ± ascites</p>
<p class="bl1">Treatment: avoid chest tube (↑ complications); Rx same as ascites (TIPS if refractory). Indwelling pleural catheter potential option if refractory <span class="s1r">(<i class="calibre3">Chest</i> 2019;155:307)</span></p>
<p class="bl1">Spontaneous <i class="calibre3">empyema</i> can occur (even w/o SBP) → dx thoracentesis; Rx abx</p>
<p class="h2a">Spontaneous bacterial peritonitis <span class="s2">(SBP; see “Ascites”;</span> <span class="s"><i class="calibre3">Eur J Gastro Hep</i> 2016;28:e10)</span></p>
<p class="bl"><span class="sbl">•</span> Develops in ~20%; 20% mortality; risk factors: ascitic TP &lt;1 g/dL, hx of SBP, current GIB</p>
<p class="bl"><span class="sbl">•</span> Can p/w encephalopathy, abd pain, fever, <i class="calibre3">but often</i> (<i class="calibre3">25%</i>) <i class="calibre3">asx;</i> perform paracentesis in all hospitalized cirrhotics w/ ascites</p>
<p class="bl"><span class="sbl">•</span> Micro: GNRs (<i class="calibre3">E. coli, Klebs</i>) &gt; GPCs (<i class="calibre3">S. pneumo, enterococcus</i>) (see “Ascites”)</p>
<p class="bl"><span class="sbl">•</span> Rx: 3<sup class="calibre15">rd</sup>-gen. ceph <i class="calibre3">or</i> amox/clav × 5 d. If uncomplicated (no enceph. or AKI) can use FQ but avoid in ↑ FQ resist. area. ↑ rate MDR organisms, incl. ESBL &amp; carbapenemase. IV albumin 1.5 g/kg at time of dx &amp; 1 g/kg on day 3 → ↑ survival <span class="s1r">(<i class="calibre3">NEJM</i> 1999;341:403)</span>; con- sider using only if Cr &gt;1 mg/dL, BUN &gt;30 mg/dL or Tbili &gt;4 mg/dL <span class="s1r">(<i class="calibre3">Gut</i> 2007 56:597)</span>. If not improving, repeat paracentesis at 48 h: expect 25% ↓ in PMNs if Rx working.</p>
<p class="bl"><span class="sbl">•</span> Indefinite Ppx if (1) h/o SBP or (2) ascitic TP &lt;1.5 plus: Na ≤130 or Cr ≥1.2 or BUN ≥25 or [CPS ≥9 + Tbili ≥3] <span class="s1r">(<i class="calibre3">Am J Gastro</i> 2009;4:993)</span> → cipro 500 mg qd or Bactrim DS qd. Short-term Ppx: CTX 1 g IV × 7d if GIB (Δ to cipro 500 bid/Bactrim DS bid when eating).</p>
<p class="h2a">Gastroesophageal varices <span class="s2">±</span> UGIB <span class="s2">(see also “GIB”;</span> <span class="s"><i class="calibre3">Hepatology</i> 2017;65:310</span><span class="s2">)</span></p>
<p class="bl"><span class="sbl">•</span> Presence of varices correlates w/ severity of liver dis (40% of Child A Pts → 85% Child C)</p>
<p class="bl"><span class="sbl">•</span> ↑ varix size, Child B/C, &amp; red wale marks assoc w/ ↑ risk of bleeding</p>
<p class="bl"><span class="sbl">•</span> UGIB 1° prevention: screen at time of dx w/ EGD; data best for Pts w/ med-large varices</p>
<p class="bl1"><b class="calibre4">nonselective β-blockers:</b> ~50% ↓ risk of bleeding &amp; ↓ mortality if med-large varices. Nadolol, propranolol, or carvedilol; latter ↓ MAP &amp; HVPG more than propranolol; delays progression of varices <span class="s1r">(<i class="calibre3">Gut</i> 2017;66:1838)</span>; may use in Pts w/ HTN. Titrate to max tolerated dose; EGD not req. to document improvement. Hold for criteria listed above.</p>
<p class="bl1"><b class="calibre4">endoscopic variceal ligation</b> (EVL): superior to βB in ↓ risk of 1<sup class="calibre15">st</sup> bleed but no diff in mortality <span class="s1r">(<i class="calibre3">Ann Hep</i> 2012;11:369)</span>; risk of serious complications (esoph perf, ulcers). Repeat q1–2wk until varices gone, w/ f/u EGD at 3 mo then q6–12mo.</p>
<p class="bl1">βB vs. EVL: choice based on Pt/physician preference, βB often 1<sup class="calibre15">st</sup> <span class="s1r">(<i class="calibre3">Hepatology</i> 2017;65:310)</span>; using both βB and EVL for primary ppx currently not recommended</p>
<p class="bl"><span class="sbl">•</span> 2° prevention: for all Pts after 1<sup class="calibre15">st</sup> bleed, given ~50% risk of rebleed &amp; ~30% mortality βB + EVL &gt; either alone; TIPS if refractory, or consider in Child B/C w/in 72 h of admission for EV bleed (↓ rebleeding, ↑ enceph., ∅ Δ mort.) <span class="s1r">(<i class="calibre3">Hepatology</i> 2016;63:581)</span></p>
<p class="h2a">Hepatic encephalopathy (HE) <span class="s">(<i class="calibre3">NEJM</i> 2016;375:1660)</span></p>
<p class="bl"><span class="sbl">•</span> Pathogenesis: failure of liver to detoxify NH<sub class="calibre8">3</sub> + other substances (eg, ADMA; <i class="calibre3">J Hepatol</i> 2013;58:38) that cause cerebral edema, ↓ O<sub class="calibre8">2</sub> consumption, ↑ ROS → brain dysfxn</p>
<p class="bl"><span class="sbl">•</span> Precipitants: bleeding, infxn, med nonadherence, ↓ K, ↓ Na, dehydration, hypoxia, portosystemic shunt (eg, TIPS), meds (eg, sedatives), acute insult to liver (eg, PVT)</p>
<p class="bl"><span class="sbl">•</span> Stages: see section in “Acute Liver Failure”</p>
<p class="bl"><span class="sbl">•</span> Dx: NH<sub class="calibre8">3</sub> levels have poor Se for dx &amp; monitoring Rx; remains a <i class="calibre3">clinical dx</i></p>
<p class="bl"><span class="sbl">•</span> Rx<i class="calibre3">:</i> identify/correct precipitants; <b class="calibre4">lactulose</b> (acidification of colon: NH<sub class="calibre8">3</sub> → NH<sub class="calibre8">4</sub><sup class="calibre15">+</sup>) w/ goal 2–4 stools/d (PEG may be more effective; <i class="calibre3">JAMA IM</i> 2014;174:1727); alternatively, <b class="calibre4">rifaximin</b> 550 mg bid (↓ gut bacteria → ↓ NH<sub class="calibre8">3</sub> prod; ? benefit to adding rifaximin to lactulose; <i class="calibre3">Am J Gastro</i> 2013;108:1458); adding albumin may speed resolution &amp; ↓ mort. <span class="s1r">(<i class="calibre3">J Gastro Hep</i> 2017;32:1234)</span></p>
<p class="bl"><span class="sbl">•</span> 2° prevention: lactulose or rifaximin 550 mg bid <span class="s1r">(<i class="calibre3">Aliment Pharmacol Ther</i> 2015;41:39)</span></p>
<p class="h2a">Hepatorenal syndrome (HRS) <span class="s">(<i class="calibre3">Am J Kidney Dis</i> 2016;67:318; <i class="calibre3">Gastro</i> 2016;150:1525)</span></p>
<p class="bl"><span class="sbl">•</span> Pathophys: splanchnic vasodilation and renal vasoconstriction w/ ↓ renal blood flow</p>
<p class="bl"><span class="sbl">•</span> Criteria: (1) cirrhosis w/ ascites; (2) <b class="calibre4">acute kidney injury</b> (serum Cr ↑ ≥0.3 mg/dL w/in 48 h or ≥50% ↑ in serum Cr from baseline; <i class="calibre3">Gut</i> 2015;64:531); (3) ∅ improvement in Cr after d/c diuretic &amp; volume expansion (1 g/kg/d of albumin × 2 d); (4) ∅ shock (prerenal azotemia/ATN); (5) ∅ nephrotoxic meds; (6) ∅ intrinsic kidney disease</p>
<p class="bl1"><a id="page_3-23" class="calibre1"></a><b class="calibre4">AKI-HRS:</b> development in &lt;2 wk; usually occurs in severe liver failure, often following precipitating event (see later); median survival 2 wk</p>
<p class="bl1"><b class="calibre4">CKD-HRS:</b> more indolent, median survival 6 mo; liver failure present &lt; than in AKI-HRS</p>
<p class="bl"><span class="sbl">•</span> Precipitants: GIB, overdiuresis, infection, serial LVP, drugs (aminoglycosides, NSAIDs)</p>
<p class="bl"><span class="sbl">•</span> Rx: <i class="calibre3">if critically ill</i> → vasopressor (eg, norepinephrine or vasopressin) + albumin (1 g/kg, max 100 g, bolus daily) to ↑ MAP 10 mmHg. <i class="calibre3">If not critically ill</i> → octreotide (100–200 mcg SC tid) + midodrine (max 15 mg PO tid) + 1 g/kg (max 100 g) albumin on day of presentation followed by 20–60 g albumin qd to ↑ MAP. Serelaxin under study <span class="s1r">(<i class="calibre3">PLoS Med</i> 2017;14:e1002248)</span>. May need dialysis or TIPS as bridge to liver transplant.</p>
<p class="h2a">Hepatocellular carcinoma (HCC; qv in Heme-Onc) <span class="s">(<i class="calibre3">Gastro</i> 2016;149:1226 &amp; 150:835)</span></p>
<p class="bl"><span class="sbl">•</span> ↑‘d risk w/ cirrhosis of any type but esp. w/ viral (risk of HCC ~3–8%/y), HFE, PBC, ?α1-AT. ↑‘d by concomitant EtOH <span class="s1r">(<i class="calibre3">J Hepatol</i> 2016;65:543)</span>.</p>
<p class="bl"><span class="sbl">•</span> Clinical: asx vs. hepatic decompensation (eg, ascites, HE), PVT w/ tumor thrombus</p>
<p class="bl"><span class="sbl">•</span> Dx: screen cirrhotics q6mo w/ U/S ± AFP, though many ctrs choose dual-phase CT/MRI</p>
<p class="bl"><span class="sbl">•</span> Rx: see “HCC” in Heme-Onc</p>
<p class="h2a">Other complications</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hepatopulmonary syndrome</b> (HPS) <span class="s1r">(<i class="calibre3">Dig Dis Sci</i> 2015;60:1914)</span></p>
<p class="bl1">Abnl gas exchange (A-a gradient ≥15 or P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> &lt;80) caused by intrapulmonary vascular dilatations leading to intrapulmonary shunting</p>
<p class="bl1">S/S: platypnea-orthodeoxia, clubbing, cyanosis</p>
<p class="bl1">Dx w/ contrast echo showing “late” A-V shunting (contrast in LA 3–6 cycles after RA)</p>
<p class="bl1">Rx: O<sub class="calibre8">2</sub>; potential embolization if large vessel on CT, ? TIPS, liver tx only definitive Rx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Portopulmonary hypertension</b> (POPH) <span class="s1r">(<i class="calibre3">Expert Rev Gastro Hepatol</i> 2015;9:983)</span></p>
<p class="bl1">Pulm HTN in Pt w/ portal HTN w/o other cause. ESLD→ ↑ endothelin→ pulm vasoconst.</p>
<p class="bl1">Rx w/ same therapies as for idiopathic PAH, incl prostacyclin analogs, endothelin receptor antagonists, sildenafil; liver transplant is often curative</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cirrhotic cardiomyopathy:</b> ↓ inotropic &amp; chronotropic response, ↓ systolic &amp; diastolic fxn, ↑ QT, hyperkinetic circulation; ↑ troponin, BNP <span class="s1r">(<i class="calibre3">World J Gastro</i> 2017;21:11503)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infxns:</b> unless already immune, vaccinate for HAV, HBV, PCV13 &amp; PPSV23; flu yearly. Cellulitis in ~20% of Pts hospitalized w/ cirrhosis, often in abd wall or LE a/w skin edema.</p>
<p class="bl"><span class="sbl">•</span> Endocrine: diabetes (15–30%), ↑ frequency of adrenal insuffic. <span class="s1r">(<i class="calibre3">Dig Dis Sci</i> 2017;62:1067)</span></p>
<p class="bl"><span class="sbl">•</span> Coagulopathy: balanced defects w/ ↓ synth of coag factors, hyperfibrinolysis, ↓ plt balanced by ↓ synthesis anticoag factors (protein C/S), defic. of profibrinolytic factors, ↑ levels of vWF. No support for routine administration of FFP, plt, cryo unless in DIC.</p>
<p class="bl"><span class="sbl">•</span> Nutrition: monitor and supplement fat-soluble vitamins, zinc</p>
<p class="bl"><span class="sbl">•</span> Meds: acetaminophen can be used up to 2 g/d; avoid ASA/NSAIDs; aminoglycosides contraindicated; oral hypoglycemics if compensated but insulin if decompensated</p>
<p class="h2a">Liver transplantation</p>
<p class="bl"><span class="sbl">•</span> Undertake evaluation when MELD ≥15. Exception points added if HCC as above, HPS</p>
<p class="bl"><span class="sbl">•</span> Indic: recurrent/severe enceph, refractory ascites, recurrent variceal bleeding, HRS, HPS, PPH, HCC (if no single lesion is &gt;5 cm <i class="calibre3">or</i> ≤3 lesions with largest ≤3 cm), ALF</p>
<p class="bl"><span class="sbl">•</span> Contraindic: inadequate social support, active substance abuse (EtOH w/in 6 mo), sepsis, advanced cardiopulm dis., extrahepatic Ca, cholangio Ca, hemangiosarcoma, persistent noncompliance, AIDS, ALF w/ sustained ICP &gt;50 mmHg or CPP &lt;40 mmHg</p>
<p class="bl"><span class="sbl">•</span> Survival: 1-y up to 90%, 5-y up to 80%, though lower with HCV; autoimmune liver disease, such as AIH/PBC/PSC may recur in 10–30% (or more) of allografts</p>
<p class="h">O<small class="calibre30">THER</small> E<small class="calibre30">TIOLOGIES</small> <small class="calibre30">OF</small> C<small class="calibre30">IRRHOSIS</small></p>
<p class="h2a">Hemochromatosis &amp; iron overload syndromes <span class="s">(<i class="calibre3">Lancet</i> 2016;388:706)</span></p>
<p class="bl"><span class="sbl">•</span> Recessive disorder of iron sensing or transport leading to tissue <b class="calibre4">iron deposition</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HFE</b> mutations (85% of cases): typically C282Y homozyg. (~0.5% of N. Europeans), rarely C282Y/H63D compound heterozyg. C282Y homozygotes: 28% of ♂ &amp; 1% of ♀ develop sx (delayed since menses ↓ Fe load). C282Y/H63D: only 1.5% manifest dis.</p>
<p class="bl"><span class="sbl">•</span> Non-HFE mutations: hemojuvelin, hepcidin, transferrin receptor 2, &amp; ferroportin</p>
<p class="bl"><span class="sbl">•</span> 2° causes of iron overload: iron-loading anemias (eg, thalassemia major, sideroblastic anemia, aplastic anemia), parenteral iron-overload (RBC transfusions, long-term HD), chronic liver disease (due to ETOH, HBV, HCV, NASH, etc.), dietary iron overload</p>
<p class="bl"><span class="sbl">•</span> Sx: fatigue &amp; arthralgias, loss of libido in ♂. In <i class="calibre3">advanced disease</i> (rare): bronze skin (melanin + iron), hypogonadism (esp. in juvenile onset), DM, arthropathy (MCP), CHF, infxns (↑ risk <i class="calibre3">Vibrio</i>, <i class="calibre3">Listeria</i>, <i class="calibre3">Yersinia</i>), cirrhosis (↑ risk if EtOH/fatty liver disease; 15% risk of HCC). Disease also a/w ALS (H63D homozygotes) &amp; porphyria.</p>
<p class="bl"><span class="sbl">•</span> Dx: iron sat &gt;45% (iron/TIBC × 100%); ↑ ferritin (acute phase reactant, so poor Sp; often nl in young Pts). If ↑ iron sat. → ✔ HFE to confirm dx, imaging by MRI (black liver). If HFE ⊕ &amp; ferritin &gt;1000 ng/mL or ↑ LFTs → liver bx for quant Fe index &amp; to stage fibrosis</p>
<p class="bl"><a id="page_3-24" class="calibre1"></a><span class="sbl">•</span> Treatment: phlebotomy (250 mL = 1 unit, ~250 mg of Fe) qwk until Fe sat &lt;50% &amp; ferritin 50–100 µg/L, then q3–4mo; PPI ↓ intestinal Fe absorption &amp; may ↓ need for phlebotomy; avoid vit C &amp; uncooked seafood; deferoxamine if phleb. contraindic.; genetic counseling</p>
<p class="h2a">Wilson disease <span class="s">(<i class="calibre3">World J Hepatol</i> 2015;7:2859)</span></p>
<p class="bl"><span class="sbl">•</span> Recessive disorder of copper transport (mutation in <i class="calibre3">ATP7B</i>) → <b class="calibre4">copper overload;</b> primarily affects liver, but also other tissues (brain, eye)</p>
<p class="bl"><span class="sbl">•</span> Epidemiology: 1 in ~30,000, but true allele frequency may be higher due to underdiagnosis; age of presentation generally ranges from 3 to 55 y</p>
<p class="bl"><span class="sbl">•</span> Extrahepatic s/s: neuro ψ disease, parkinsonism &amp; movement disorder (hepatolenticular disease), Kayser-Fleischer rings (⊕ in 99% w/ neuro ψ but in &lt;50% w/ hepatic disease), Coombs ⊖ hemolytic anemia, renal disease</p>
<p class="bl"><span class="sbl">•</span> Dx: ↑ 24-h urine Cu, ↓ serum ceruloplasmin (Se 90%), rarely penicillamine challenge w/ ↑ urine Cu excretion, liver bx w/ hepatic Cu content. In <i class="calibre3">acute liver failure</i>, Aϕ/bili &lt;4 + AST/ALT &gt;2.2 better Se &amp; Sp than urine Cu or ceruloplasmin <span class="s1r">(<i class="calibre3">Hepatology</i> 2008;4:1167)</span>.</p>
<p class="bl"><span class="sbl">•</span> Treatment: <b class="calibre4">chelation</b> w/ <small class="calibre40">D</small>-penicillamine (supplement B6 as <small class="calibre40">D</small>-pen inactivates); alternative is trientine (↓ toxicity w/ ≈ efficacy, but $$). <b class="calibre4">Zinc:</b> ↓ intestinal Cu transport &amp; can help delay disease; best used in conjunction w/ chelation (must give 4–5 h apart from chelators). Elim. Cu-rich foods. Transplant for ALF or for chronic dis. unresponsive to Rx.</p>
<p class="h2a">α<sub class="calibre8">1</sub>-antitrypsin deficiency (α<sub class="calibre8">1</sub>-AT) <span class="s">(<i class="calibre3">J Hepatol</i> 2016;65:413)</span></p>
<p class="bl"><span class="sbl">•</span> Abnl α<sub class="calibre8">1</sub>-AT → polymerization in liver (cirrhosis) &amp; uninhibited protease activity in lung (emphysema). Affects 1/3000 of European ancestry. Varied presentations: neonatal hepatitis; cholestatic jaundice in children; ↑ AST/ALT or cirrhosis in children/adults.</p>
<p class="bl"><span class="sbl">•</span> Extrahepatic disease includes: emphysema, necrotizing panniculitis, ANCA vasculitis</p>
<p class="bl"><span class="sbl">•</span> Dx: serum α<sub class="calibre8">1</sub>-AT level (acute phase reactant), level &lt;50% of nl typically diagnostic;</p>
<p class="bl1">gold standard = phenotyping of protease inhibitor (Pi). Alleles most a/w hepatic dis.: Z (63% of ZZ adults have chronic liver dis. and liver fibrosis may be present in 35% of ZZ individuals w/o overt liver disease) &amp; M (malton) <span class="s1r">(<i class="calibre3">J Hepatol</i> 2018;69(6)</span>:1357). Liver bx shows characteristic PAS ⊕ cytoplasmic inclusion bodies.</p>
<p class="bl"><span class="sbl">•</span> Treatment: standard Rx for cirrhosis/chronic liver dis., including liver transplantation</p>
<p class="h2a">Primary biliary cholangitis (PBC) <span class="s">(<i class="calibre3">Lancet</i> 2015;386:1565)</span></p>
<p class="bl"><span class="sbl">•</span> Autoimmune destruction of <i class="calibre3">intrahepatic</i> bile ducts (previously “primary biliary cirrhosis”)</p>
<p class="bl"><span class="sbl">•</span> Epi: ♀ 40–60 y; a/w Sjögren’s, Raynaud’s, scleroderma, celiac &amp; thyroid disease; may be triggered by certain infxns or toxins; a/w X monosomy, variants in IL12α &amp; IL12R genes</p>
<p class="bl"><span class="sbl">•</span> Sx (late): fatigue/sleep disturbance, pruritus, steatorrhea, xanthelasma, jaundice, cirrhosis</p>
<p class="bl"><span class="sbl">•</span> Ddx: PSC, AIH, hepatic sarcoidosis, meds, idiopathic adult ductopenia, biliary stricture/Ca</p>
<p class="bl"><span class="sbl">•</span> Dx: ↑ Aϕ, ↑ bili, ↑ IgM, ↑ chol, ⊕ antimitochondrial Ab (AMA) in 95%. If ⊕ AMA, liver bx not needed due to high Se &amp; Sp. 0.5% gen pop ⊕ AMA &amp; nl LFTs → 10% develop PBC at 6 y. If AMA ⊖, liver bx (Pts often ⊕ ANA, smooth muscle Ab; same prognosis as ⊕ AMA).</p>
<p class="bl"><span class="sbl">•</span> Rx: <b class="calibre4">ursodeoxycholic acid</b> (13–15 mg/kg/d) regardless of stage (30% of Pts untreated!)</p>
<p class="bl1">~25% complete response, ↑ survival &amp; ↓ histologic change &amp; complications (eg, varices). Biochemical response predicts clinical outcomes <span class="s1r">(<i class="calibre3">Clin Gastro Hep</i> 2018;16:1342)</span>.</p>
<p class="bl1">Bezafibrate (not available in U.S. but fenofibrate similar) appears to be effective 2<sup class="calibre15">nd</sup>-line agent in combo w/ UDCA if inadequate response to UDCA <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:2171)</span></p>
<p class="bl1">Obeticholic acid (5 → 10 mg qd, except CPS B/C: 5 mg/wk → 10 mg twice weekly) ↓ Aφ, but no fat-soluble vitamins; screen/Rx osteoporosis fibrosis <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:631)</span></p>
<p class="bl1">Pruritus: cholestyramine (give 2–4 h after UDCA); if refractory sx: naltrexone, rifampin</p>
<p class="bl1">Fat-soluble vitamins; screen/Rx osteoporosis (risk independent of vit D deficiency)</p>
<p class="bl1">If ESLD: liver tx; ~20% recur but no impact on long-term survival</p>
<p class="h2a">Primary sclerosing cholangitis (PSC) <span class="s">(<i class="calibre3">NEJM</i> 2016;375:1161; <i class="calibre3">Lancet</i> 2018;391:2547)</span></p>
<p class="bl"><span class="sbl">•</span> Diffuse inflammation of <i class="calibre3">intrahepatic and extrahepatic</i> bile ducts leading to fibrosis &amp; stricturing of biliary system. A/w HLA-B8 and -DR3 or -DR4, frequent ⊕ autoantibodies.</p>
<p class="bl"><span class="sbl">•</span> Epi: ♂ &gt; ♀ (20–50 y) ~70% Pts w/ PSC have IBD (usually UC); only 1–4% w/ UC have PSC. ⊕ prognostic factors: ♂, absence of IBD, small duct PSC <span class="s1r">(<i class="calibre3">Gastro</i> 2017;152:1829)</span>.</p>
<p class="bl"><span class="sbl">•</span> Clinical: fatigue, pruritus, jaundice, fevers, RUQ pain, concomitant IBD, ESLD</p>
<p class="bl"><span class="sbl">•</span> Ddx: extrahepatic obstruction, PBC, may also have overlap w/ AIH and similar presentation to IgG4 autoimmune cholangitis (steroid responsive) <span class="s1r">(<i class="calibre3">J Gastro</i> 2016;51:295)</span></p>
<p class="bl"><span class="sbl">•</span> Dx: MRCP ± ERCP → <i class="calibre3">multifocal beaded bile duct strictures</i>, but may miss dx if confined to small intrahepatic ducts (~2% “small duct PSC”:? different disease). Aφ predicts survival. Liver bx may show “onion-skin” fibrosis around bile ducts but not necessary for dx.</p>
<p class="bl"><span class="sbl">•</span> Treatment: supportive care, fat-soluble vitamins; no meds have improved survival Ursodeoxycholic acid may ↓ colon Ca risk in Pts w/ UC &amp; improve LFTs in Pts w/o UC</p>
<p class="bl1">Dominant stricture: endoscopic dilation, short-term stenting or surgical resection</p>
<p class="bl1">Cholangiocarcinoma (20%): ? biannual surveillance w/ MRCP/RUQ U/S and CA19-9</p>
<p class="bl1">Liver transplantation: ~30% recurrence, though if UC, colectomy may ↓ recurrence</p>
<h2 class="ct"><a id="h51" class="calibre7"></a><a id="page_3-25" class="calibre7"></a><a href="part0002.html#rh57" class="calibre7">HEPATIC VASCULAR DISEASE</a></h2>
<p class="h2a">Portal vein thrombosis (PVT) <span class="s">(<i class="calibre3">Clin Liver Dis</i> 2017;10:152)</span></p>
<p class="bl"><span class="sbl">•</span> Definition: thrombosis, constriction or invasion of portal vein; may lead to portal HTN</p>
<p class="bl"><span class="sbl">•</span> Etiologies: cirrhosis, neoplasm (pancreas, HCC), abdominal infxn, hypercoag states (qv), pancreatitis, collagen vascular diseases, Behçet’s, IBD, surgery, trauma, OCPs, preg</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations</p>
<p class="bl1"><b class="calibre4">acute:</b> can p/w abd or lumbar pain, or asx w/ incidental finding on U/S or CT. If mesenteric vein involved may p/w intestinal infarct. If fever, consider pylephlebitis.</p>
<p class="bl1"><b class="calibre4">chronic:</b> asx/incidental finding; may p/w s/s of <b class="calibre4">portal HTN</b> → hematemesis 2° variceal bleeding, splenomegaly, encephalopathy; ascites uncommon unless cirrhosis</p>
<p class="bl"><span class="sbl">•</span> Dx: LFTs usually nl; begin w/ U/S w/ Doppler, confirm w/ MRA or CT (I<sup class="calibre15">+</sup>), angio; consider hypercoag w/u. “Portal cavernoma”: network of hepatopetal collaterals in chronic PVT—can rarely cause biliary obstruction &amp; cholestatic LFTs = portal cholangiopathy.</p>
<p class="bl"><span class="sbl">•</span> Treatment: <b class="calibre4">Acute:</b> If noncirrhotic, LMWH → warfarin × 6 mo, or indefinitely if irreversible cause. If cirrhotic, anticoag ↑ recanalziation w/o ↑ bleeding <span class="s1r">(<i class="calibre3">Gastro</i> 2017;153:480)</span>; screen for high-risk varices prior to Rx <span class="s1r">(<i class="calibre3">Nat Rev Gastro Hep</i> 2014;11:435)</span>. DOACs under investigation.</p>
<p class="bl1"><b class="calibre4">Chronic:</b> Anticoag if noncirrhotic or hypercoag state. If cirrhotic, consider if sx or progression. In all, screen for varices; if present, variceal bleed ppx prior to anticoag.</p>
<p class="h2a">Splenic vein thrombosis</p>
<p class="bl"><span class="sbl">•</span> Can occur 2/2 local inflam. (eg, panc.). Can p/w isol. gastric varices. Splenectomy curative.</p>
<p class="h2a">Budd-Chiari syndrome <span class="s">(<i class="calibre3">World J Hepatol</i> 2016;8:691)</span></p>
<p class="bl"><span class="sbl">•</span> Hepatic outflow obstruction 2/2 occlusion of hepatic vein(s) or IVC → sinusoidal congestion and portal HTN. Can be 1° (eg, thrombosis) or 2° (eg, extravascular compression).</p>
<p class="bl"><span class="sbl">•</span> Etiol.: ~50% due to myeloprolif. d/o a/w <i class="calibre3">JAK2</i> mutations (esp. <i class="calibre3">P. vera</i>), other hypercoag state (qv), tumor invasion (HCC, renal, adrenal), IVC webs, trauma, 25% idiopathic</p>
<p class="bl"><span class="sbl">•</span> Symptoms: hepatomegaly, RUQ pain, ascites, dilated venous collaterals, acute liver failure</p>
<p class="bl"><span class="sbl">•</span> Dx: ± ↑ aminotransferases &amp; Aϕ; Doppler U/S of hepatic veins (85% Se &amp; Sp); CT (I<sup class="calibre15">+</sup>) or MRI/MRV → vein occlusion or ↑ caudate lobe (separate venous drainage); “spider- web” pattern on hepatic venography; liver bx showing congestion (r/o right-sided CHF)</p>
<p class="bl"><span class="sbl">•</span> Treatment: Rx underlying condition, anticoag (LMWH → warfarin); consider thrombolysis acutely; if short stenosis, stent may be possible; consider TIPS (↑ occlusion risk c/w side-to-side portocaval shunt); liver transplant if ALF or failed shunt <span class="s1r">(<i class="calibre3">J Gastro Surg</i> 2012;16:286)</span></p>
<p class="h2a">Sinusoidal obstruction syndrome (SOS) <span class="s">(<i class="calibre3">Bone Marrow Transplant</i> 2015;50:781)</span></p>
<p class="bl"><span class="sbl">•</span> Occlusion of hepatic venules &amp; sinusoids (formerly veno-occlusive disease) 2/2 toxic insult</p>
<p class="bl"><span class="sbl">•</span> Etiologies: HSCT, chemo (esp. cyclophosphamide), XRT, Jamaican bush tea</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: hepatomegaly, RUQ pain, ascites, weight gain, ↑ bilirubin</p>
<p class="bl"><span class="sbl">•</span> Dx: U/S w/ reversal of portal flow, but often not helpful; dx made clinically (↑ bili, wt gain/ascites and RUQ pain) or, if necessary, by liver bx or HVPG (&gt;10 mmHg)</p>
<p class="bl"><span class="sbl">•</span> Rx (20% mort.): supportive, fluid mgmt (diuretics); ? defibrotide (adenosine agonist ↑ TPA)</p>
<p class="bl"><span class="sbl">•</span> Ppx: defibrotide; ursodeoxycholic acid for high-risk HSCT pop; ? use of low-dose heparin</p>
<p class="capf"><b class="calibre4">Figure 3-6</b> Normal hepatic vasculature</p>
<p class="fn1">Modified from The Nature of Disease Pathology for the Health Professions, 2007. Hepatology 2009;49:1729.</p>
<p class="image"><img src="../images/00060.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="h52" class="calibre7"></a><a id="page_3-26" class="calibre7"></a><a href="part0002.html#rh58" class="calibre7">ASCITES</a></h2>
<p class="h2a">Pathophysiology</p>
<p class="bl"><span class="sbl">•</span> In portal hypertension → systemic vasodilatation (? due to release of NO) → ↓ effective arterial volume → renal Na retention → volume overload and ascites</p>
<p class="bl"><span class="sbl">•</span> In malignant or inflammatory ascites, leaking of proteinaceous material occurs from tumor or from inflamed/infected/ruptured intraabdominal structures</p>
<p class="h2a">Symptoms</p>
<p class="bl"><span class="sbl">•</span> ↑ abd girth, wt gain, new abd hernia, abd pain, dyspnea, nausea, early satiety</p>
<p class="h2a">Evaluation <span class="s">(<i class="calibre3">World J Hepatol</i> 2013;5:251; <i class="calibre3">JAMA</i> 2016;316:340)</span></p>
<p class="bl"><span class="sbl">•</span> Physical exam: flank dullness (&gt;1500 mL needed), shifting dullness (Se ~83%)</p>
<p class="bl"><span class="sbl">•</span> Radiologic: <b class="calibre4">U/S</b> detects &gt;100 mL; MRI/CT (also help with Ddx)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Paracentesis</b> <span class="s1r">(<i class="calibre3">Hep</i> 2013;57:1651)</span>: perform in all Pts w/ new ascites, consider in all hosp. cirrhotics w/ ascites. Low complic. rate (~1% hematoma formation). Prophylactic FFP or plts does <i class="calibre3">not</i> ↓ bleeding complic. Most useful tests: cell count, alb, total protein, culture.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Serum-ascites albumin gradient (SAAG):</b> serum alb (g/dL) – ascites alb (in g/dL)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre36"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabhead"><b class="calibre4">Portal HTN Related (SAAG</b> ≥<b class="calibre4">1.1)</b></p></td>
<td class="bg0-b"><p class="tabhead"><b class="calibre4">Non–portal HTN Related (SAAG</b> &lt;<b class="calibre4">1.1)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><i class="calibre3">Presinusoidal</i> obstruction</p>
<p class="tab1">portal or splenic vein thrombosis, schisto-</p>
<p class="tab1">somiasis, sarcoidosis</p>
<p class="tab"><i class="calibre3">Sinusoidal</i> obstruction:</p>
<p class="tab1"><b class="calibre4">cirrhosis</b> (81%), acute hepatitis, malignancy (HCC or mets)</p>
<p class="tab"><i class="calibre3">Postsinusoidal</i> obstruction</p>
<p class="tab">Right-sided <b class="calibre4">CHF</b> (ex: constriction, TR), Budd-Chiari syndrome, SOS</p></td>
<td class="bg"><p class="tabh"><b class="calibre4">Malig:</b> peritoneal carcinomatosis; chylous ascites from malignant lymphoma; Meigs’ syndrome (ovarian tumor)</p>
<p class="tabh"><b class="calibre4">Infection:</b> TB, chlamydia/gonorrhea (ie, Fitz-Hugh-Curtis syndrome)</p>
<p class="tabh">Inflam: pancreatitis, ruptured pancreatic/biliary/lymph duct; bowel obstrxn</p>
<p class="tabh">Hypoalbuminemic states: <b class="calibre4">nephrotic syndrome</b>, protein-losing enteropathy</p></td>
</tr>
</table>
<p class="bl1">SAAG &gt;1.1 diagnoses portal HTN with ~97% accuracy</p>
<p class="bl1">If portal HTN + another cause (seen in ~5% of cases) SAAG still ≥1.1</p>
<p class="bl"><span class="sbl">•</span> Ascites fluid total protein (<b class="calibre4">AFTP</b>): useful when SAAG ≥1.1 to distinguish cirrhosis (AFTP &lt;2.5 g/dL) from cardiac ascites (AFTP ≥2.5 g/dL). Low AFTP (&lt;1 g/dL) assoc. w/ ↑ risk of SBP (see “Cirrhosis” for guidelines on SBP Ppx based on AFTP).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cell count:</b> normal limit of PMNs in ascitic fluid up to 250 PMNs/mm<sup class="calibre15">3</sup>. Bloody tap (typically from traumatic para) can skew cell count; subtract 1 PMN for every 250 RBCs to correct PMN count. Ascitic PMNs ≥250 suggest infection (see below).</p>
<p class="bl"><span class="sbl">•</span> Other tests: amylase (pancreatitis, gut perforation); bilirubin (test in dark brown fluid, suggests bile leak or proximal intestinal perf); TG (chylous ascites); BNP (HF); cytology (peritoneal carcinomatosis, ~95% Se w/ 3 samples). SBP a/w ↓ glc &amp; ↑ LDH.</p>
<p class="h2a">Treatment <span class="s2">(see “Cirrhosis” for details)</span></p>
<p class="bl"><span class="sbl">•</span> If 2° to portal HTN: ↓ <b class="calibre4">Na intake</b> + <b class="calibre4">diuretics;</b> if refractory → LVP or TIPS</p>
<p class="bl"><span class="sbl">•</span> If non–portal HTN related: depends on underlying cause (TB, malignancy, etc.)</p>
<p class="h2a">Bacterial peritonitis <span class="s">(<i class="calibre3">Gut</i> 2012;61:297)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre28"/>
<col class="calibre29"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b1"><p class="tabhead"><b class="calibre4">Ascites PMN</b></p></td>
<td class="bg1-b1"><p class="tabheadc">⊕ <b class="calibre4">Ascites Culture</b></p></td>
<td class="bg1-b1"><p class="tabheadc">⊖ <b class="calibre4">Ascites Culture</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">≥ <b class="calibre4">250/µL</b></p></td>
<td class="bg0-br"><p class="tabh"><b class="calibre4">Spontaneous bacterial peritonitis (SBP):</b> gut bacterial translocation to ascites. In cirrhosis, ↓ ascites opsonins (esp. if ↓AFTP) ↑ risk of infxn. Cx w/ 1 org: <i class="calibre3">E. coli</i> (37%), <i class="calibre3">Klebs</i> (17%), <i class="calibre3">S. pneumo</i> (12%), misc. GPC (14%), misc. GNR (10%)</p>
<p class="tabh"><b class="calibre4">2° bacterial peritonitis:</b> 2/2 intra-abd abscess, perf. Runyon’s criteria: AFTP &gt;1 g/dL, glc &lt;50 mg/dL, LDH &gt;ULN for serum. Cx polymicrobial. Rx 3<sup class="calibre35">rd</sup>-gen ceph. + MNZ; urgent abd imaging ± ex lap.</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Culture-</b>⊖ <b class="calibre4">neutrocytic ascites (CNNA):</b> cell counts suggest infxn but cx ⊖. No recent abx, w/o other explan. for counts. Rare when sens cx methods.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">&lt;<b class="calibre4">250/µL</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Nonneutrocytic bacterascites (NNBA):</b> ⊕ cx w/o ↑ PMNs. Natural course may resolve w/o Rx or may progress to SBP.</p>
<p class="tab">Cx w/ 1 org.: Misc. GPC (30%), <i class="calibre3">E. coli</i> (27%), <i class="calibre3">Klebs</i> (11%), misc. GNR (14%)</p></td>
<td class="bg0-b"><p class="tab">(Normal)</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="3"><p class="tab"><b class="calibre4">Peritoneal dialysis-associated:</b> cloudy fluid, abd pain, fever, nausea.</p>
<p class="tab">≥100 WBCs/µL, poly predom. Cx ⊕ (typ. 1 org.): Misc. GPC (50%), misc. GNR (15%).</p>
<p class="tab">Rx: vanc + gent (IV load, then administer in PD).</p></td>
</tr>
</table>
<h2 class="ct"><a id="h53" class="calibre7"></a><a id="page_3-27" class="calibre7"></a><a href="part0002.html#rh59" class="calibre7">BILIARY TRACT DISEASE</a></h2>
<p class="h">C<small class="calibre30">HOLELITHIASIS</small> (G<small class="calibre30">ALLSTONES</small>)</p>
<p class="h2a">Epidemiology &amp; pathogenesis <span class="s">(<i class="calibre3">J Hepatol</i> 2016;65:146; <i class="calibre3">Gastro</i> 2016;151:351)</span></p>
<p class="bl"><span class="sbl">•</span> Affects 10–20% of Western populations</p>
<p class="bl"><span class="sbl">•</span> Bile = bile salts, phospholipids, cholesterol; ↑ cholesterol saturation in bile + accelerated nucleation + gallbladder hypomotility → gallstones</p>
<p class="bl"><span class="sbl">•</span> Risk factors: ♀; South, Central, Native American; ↑ age (&gt;40 y); obesity, TPN, rapid ↓ wt; dyslipidemia; preg., drugs (OCPs, estrogen, clofibrate, octreotide, Cftx); ileal dis., genetic</p>
<p class="bl"><span class="sbl">•</span> Statin use ↓ risk of sx gallstones &amp; cholecystectomy <span class="s1r">(<i class="calibre3">Hepatol Res</i> 2015;45:942)</span></p>
<p class="h2a">Types of gallstones <span class="s">(</span><i class="calibre3">J Hepatol</i> <span class="s">2016;65:146)</span></p>
<p class="bl"><span class="sbl">•</span> Cholesterol (90%): 2 subtypes</p>
<p class="bl1">mixed: contain &gt;50% cholesterol; typically smaller, multiple stones</p>
<p class="bl1">pure: 100% cholesterol; larger, yellow, white appearance</p>
<p class="bl"><span class="sbl">•</span> Pigment (10%)</p>
<p class="bl1"><i class="calibre3">Black:</i> unconjugated bili &amp; calcium; seen w/ chronic hemolysis, cirrhosis, CF, Gilbert synd</p>
<p class="bl1"><i class="calibre3">Brown:</i> stasis &amp; infxn in bile ducts → bacteria deconjugate bilirubin → precipitates w/ Ca; thus found pred in bile ducts; seen w/ duod. diverticula, biliary strictures, parasites</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Asx in ~80%. Biliary pain develops in 1–4%/y. Once sx, rate of complications ~1–3%/y.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biliary pain</b> = <b class="calibre4">episodic RUQ or epigastric pain;</b> begins abruptly, continuous, resolves slowly and lasts 30 min–3 h; ± radiation to scapula; precip by <b class="calibre4">fatty foods</b>; <b class="calibre4">nausea</b></p>
<p class="bl"><span class="sbl">•</span> Physical exam: afebrile, ± RUQ tenderness or epigastric pain</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> Labs normal in large majority</p>
<p class="bl"><span class="sbl">•</span> RUQ U/S: Se &amp; Sp &gt;95% for stones &gt;5 mm; can show complications (cholecystitis); should be performed only after fasting ≥8 h to ensure distended, bile-filled gallbladder</p>
<p class="bl"><span class="sbl">•</span> Endoscopic US (EUS) Se 94–98% in Pts w/ biliary pain but nl abd US <span class="s1r">(<i class="calibre3">J Hepatol</i> 2016;65:146)</span></p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Am Fam Physician</i> 2014;89:795; <i class="calibre3">J Hepatol</i> 2016;65:146)</span></p>
<p class="bl"><span class="sbl">•</span> Cholecystectomy (CCY), usually laparoscopic, if symptomatic</p>
<p class="bl"><span class="sbl">•</span> CCY in <i class="calibre3">asx</i> Pts if: GB calcification (↑ risk of cancer), GB polyps &gt;10 mm, Native American, stones &gt;3 cm; consider in morbidly obese undergoing bariatric surgery, cardiac Tx candidates, hemolytic anemia</p>
<p class="bl"><span class="sbl">•</span> Ursodeoxycholic acid (rare) for cholesterol stones w/ uncomplicated biliary pain or if poor surgical candidate; also reduces risk of gallstone formation with rapid wt loss</p>
<p class="bl"><span class="sbl">•</span> Pain: NSAIDs drug of choice, efficacy ≈ opiates &amp; ↓ complic.</p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Cholecystitis: 20% of sx biliary pain → cholecystitis w/in 2 y</p>
<p class="bl"><span class="sbl">•</span> Choledocholithiasis → cholangitis or gallstone pancreatitis</p>
<p class="bl"><span class="sbl">•</span> Mirizzi syndrome: common hepatic duct obstruction by cystic duct stone → jaundice, biliary obstruction</p>
<p class="bl"><span class="sbl">•</span> Cholecystenteric fistula: stone erodes through gallbladder into bowel</p>
<p class="bl"><span class="sbl">•</span> Gallstone ileus: SBO (usually at term ileum) due to stone in intestine that passed thru fistula</p>
<p class="bl"><span class="sbl">•</span> Gallbladder carcinoma: ~1% in U.S.</p>
<p class="h">C<small class="calibre30">HOLECYSTITIS</small> <span class="s1">(<i class="calibre22">J Hepatol</i> 2016;65:146; <i class="calibre22">World J Gastro Surg</i> 2017;9:118)</span></p>
<p class="h2a">Pathogenesis</p>
<p class="bl"><span class="sbl">•</span> Acute cholecystitis: stone impaction in cystic duct → inflammation behind obstruction → GB swelling ± secondary infection (50%) of biliary fluid</p>
<p class="bl"><span class="sbl">•</span> Acalculous cholecystitis: GB stasis &amp; ischemia (w/o cholelithiasis) → necroinflammation. Occurs in critically ill. A/w postop major surgery, TPN, sepsis, trauma, burns, opiates, immunosuppression, infxn (eg, CMV, <i class="calibre3">Candida</i>, <i class="calibre3">Crypto, Campylobacter</i>, typhoid fever).</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> History: RUQ/epigastric pain ± radiation to R shoulder/back, nausea, vomiting, fever</p>
<p class="bl"><span class="sbl">•</span> Physical exam: <b class="calibre4">RUQ tenderness</b>, <b class="calibre4">Murphy’s sign</b> = ↑ RUQ pain and inspiratory arrest with deep breath during palpation of R subcostal region, ± palpable gallbladder</p>
<p class="bl"><span class="sbl">•</span> Laboratory evaluation: <i class="calibre3">may</i> see ↑ WBC, ± mild ↑ bilirubin, Aφ, ALT/AST, amylase; if AST/ALT &gt;500 U/L, bili &gt;4 mg/dL or amylase &gt;1000 U/L → choledocholithiasis</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">RUQ U</b>/<b class="calibre4">S:</b> high Se &amp; Sp for stones, but need <i class="calibre3">specific signs of cholecystitis:</i> GB wall thickening &gt;4 mm, pericholecystic fluid and a sonographic Murphy’s sign</p>
<p class="bl"><a id="page_3-28" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">HIDA scan:</b> most Se test (80–90%) for acute cholecystitis. IV inj of HIDA (selectively secreted into bile). ⊕ if HIDA enters BD but not GB. 10–20% false ⊕ (cystic duct obstructed 2/2 chronic cholecystitis, lengthy fasting, liver disease).</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Ann Surg</i> 2013;258:385; <i class="calibre3">NEJM</i> 2015;373:357)</span></p>
<p class="bl"><span class="sbl">•</span> NPO, IV fluids, nasogastric tube if intractable vomiting, analgesia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antibiotics</b> (<i class="calibre3">E. coli</i>, <i class="calibre3">Klebsiella</i> and <i class="calibre3">Enterobacter</i> sp. are usual pathogens) ([2<sup class="calibre15">nd</sup>- or 3<sup class="calibre15">rd</sup>-generation cephalosporin or FQ] + MNZ) or piperacillin-tazobactam</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CCY</b> (typically laparoscopic) w/in 24 h ↓ morbidity vs. waiting 7–45 d</p>
<p class="bl"><span class="sbl">•</span> If unstable for surgery, EUS-guided transmural, ERCP-guided transcystic duct drainage, or percutaneous cholecystotomy (if w/o ascites or coagulopathy) are alternatives to CCY</p>
<p class="bl"><span class="sbl">•</span> Intraoperative cholangiogram or ERCP to r/o choledocholithiasis in Pts w/ jaundice, cholangitis or stone in BD on U/S (see below)</p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Gangrenous cholecystitis: necrosis w/ risk of empyema and perforation</p>
<p class="bl"><span class="sbl">•</span> Emphysematous cholecystitis: infection by gas-forming organisms (air in GB wall)</p>
<p class="bl"><span class="sbl">•</span> Post CCY: bile duct leak, BD injury or retained stones, cystic duct remnant, sphincter of Oddi dysfxn</p>
<p class="h">C<small class="calibre30">HOLEDOCHOLITHIASIS</small></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Gallstone lodged in common bile duct (CBD)</p>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> Occurs in 15% of Pts w/ gallbladder stones; can form de novo in CBD</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Asymptomatic</p>
<p class="bl"><span class="sbl">•</span> RUQ/epigastric pain 2° obstrxn of bile flow → ↑ CBD pressure, jaundice, pruritus, nausea</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">Gastro Endo</i> 2010;71:1; <i class="calibre3">J Hepatol</i> 2016;65:146)</span></p>
<p class="bl"><span class="sbl">•</span> Labs: ↑ bilirubin, Aϕ; transient spike in ALT or amylase suggests passage of stone</p>
<p class="bl"><span class="sbl">•</span> RUQ U/S: BD stones seen ~50–80% of cases; usually inferred from dilated CBD (&gt;6 mm)</p>
<p class="bl"><span class="sbl">•</span> ERCP preferred modality when likelihood high (eg, visualized stone, cholangitis, bili &gt;4, <i class="calibre3">or</i> dilated CBD on U/S + bili 1.8–4 mg/dL); cholangiogram (percutaneous, operative) when ERCP unavailable or unsuccessful; EUS/MRCP to exclude BD stones when suspicion intermediate (eg, no stone, but: dilated ducts on US, bili 1.8–4 mg/dL, gallstone panc., age &gt;55, or abnl non-bili LFT)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> ERCP &amp; papillotomy w/ stone extraction (± lithotripsy)</p>
<p class="bl"><span class="sbl">•</span> CCY typically w/in 6 wk unless contraindication (&gt;15% Pts will develop indication for CCY if left unRx’d)</p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Cholangitis, cholecystitis, pancreatitis, stricture</p>
<p class="h">C<small class="calibre30">HOLANGITIS</small></p>
<p class="h2a">Definition &amp; etiologies</p>
<p class="bl"><span class="sbl">•</span> BD obstruction → infection proximal to the obstruction</p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">BD stone</b> (~85%)</p>
<p class="bl1">Malignant (biliary, pancreatic) or benign stricture</p>
<p class="bl1">Infection w/ fluke (<i class="calibre3">Clonorchis sinensis</i>, <i class="calibre3">Opisthorchis viverrini</i>)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Charcot’s triad: RUQ pain, jaundice, fever/chills; present in ~70% of Pts</p>
<p class="bl"><span class="sbl">•</span> Reynolds’ pentad: Charcot’s triad + shock and Δ MS; present in ~15% of Pts</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> RUQ U/S: often demonstrates dilation</p>
<p class="bl"><span class="sbl">•</span> Labs: ↑ WBC (with left shift), bilirubin, Aφ, amylase; may see ⊕ BCx</p>
<p class="bl"><span class="sbl">•</span> ERCP; percutaneous transhepatic cholangiogram if ERCP unsuccessful</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antibiotics</b> (broad spectrum) to cover common bile pathogens (see above) ampicillin + gentamicin (or levofloxacin) ± MNZ (if severe); carbapenems; pip/tazo</p>
<p class="bl"><span class="sbl">•</span> ~80% respond to conservative Rx and abx → biliary drainage on elective basis</p>
<p class="bl"><span class="sbl">•</span> ~20% require <b class="calibre4">urgent biliary decompression</b> via ERCP (papillotomy, stone extraction and/or stent insertion). If sphincterotomy cannot be performed (larger stones), decompression by biliary stent or nasobiliary catheter can be done; otherwise, percutaneous transhepatic biliary drainage or surgery.</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0007.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0009.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
